<SEC-DOCUMENT>0001615774-15-003018.txt : 20151026
<SEC-HEADER>0001615774-15-003018.hdr.sgml : 20151026
<ACCEPTANCE-DATETIME>20151026092205
ACCESSION NUMBER:		0001615774-15-003018
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20151026
DATE AS OF CHANGE:		20151026

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-207600
		FILM NUMBER:		151174315

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>s102056_forms3.htm
<DESCRIPTION>FORM S-3
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp.: Form S-3 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B>As filed with the Securities and Exchange Commission on
October 23, 2015 </B></P>
<P align=right><B>Registration No.____-_______ </B></P>
<P align=center><B><FONT size=5>UNITED STATES </FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT><BR></B><B>Washington, D.C.
20549 </B></P>
<P align=center><B><FONT size=5>FORM S-3 </FONT><BR></B><B>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</B></P>
<P align=center><B><U><FONT size=5>ANAVEX LIFE SCIENCES CORP.
</FONT></U></B><BR><B>(Exact name of registrant as specified in its
charter)</B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="50%"><B><U>20-8365999 </U></B></TD></TR>
  <TR vAlign=top>
    <TD align=center><B>(State or other jurisdiction of </B></TD>
    <TD align=center width="50%"><B>(IRS Employer </B></TD></TR>
  <TR vAlign=top>
    <TD align=center><B>incorporation or organization) </B></TD>
    <TD align=center width="50%"><B>Identification Number)
</B></TD></TR></TABLE>
<P align=center><B>51 West 52nd Street, 7th Floor <BR></B><B>New York, NY
10019-6163 <BR></B><B><U>Telephone: 1-844-689-3939 <BR></U></B><I>(Address and
Telephone Number of Principal Executive Offices) </I><B></B></P>
<P align=center><B>Christopher Missling, PhD <BR></B><B>Chief Executive Officer
<BR></B><B>51 West 52nd Street, 7th Floor <BR>New York, NY 10019-6163
<BR></B><B><U>Telephone: 1-844-689-3939 <BR></U></B><I>(Name, Address and
Telephone Number of Agent for Service) </I></P>
<P align=center><I>Copies to: </I></P>
<P align=center><B>Clayton E. Parker, Esq. <BR></B><B>John D. Owens III, Esq.
<BR></B><B>K&amp;L Gates LLP <BR></B><B>200 South Biscayne Boulevard, Suite 3900
<BR></B><B>Miami, Florida 33131-2399 <BR></B><B>Telephone: (305) 539-3300
<BR></B><B>Facsimile: (305) 358-7095&nbsp;<BR></B><B></B></P>
<P align=center><B>Approximate Date of Proposed Sale to the Public: <BR></B>From
time to time after this Registration Statement becomes effective </P>
<P align=justify style="text-indent:5%">If the only securities being registered on this Form are being
offered pursuant to dividend or interest reinvestment plans, please check the
following box. [&nbsp;&nbsp; ]&nbsp;</P>
<P align=justify style="text-indent:5%">If any of the securities being registered on this Form are to
be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 (&#147;<U>Securities Act</U>&#148;), other than securities offered
only in connection with dividend or interest reinvestment plans, check the
following box. [X]&nbsp;</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify style="text-indent:5%">If this Form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [&nbsp;&nbsp;
]&nbsp;</P>
<P align=justify style="text-indent:5%">If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective
registration statement for the same offering. [&nbsp;&nbsp; ]&nbsp;</P>
<P align=justify style="text-indent:5%">If this Form is a registration statement pursuant to General
Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule 462(e) under the
Securities Act, check the following box. [&nbsp;&nbsp; ]&nbsp;</P>
<P align=justify style="text-indent:5%">If this Form is a post-effective amendment to a registration
statement filed pursuant to General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule
413(b) under the Securities Act, check the following box. [&nbsp;&nbsp;
]&nbsp;</P>
<P align=justify style="text-indent:5%">Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See definitions of &#147;large accelerated filer,&#148; &#147;accelerated
filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Large accelerated filer </TD>
    <TD align=left width="25%">[&nbsp;&nbsp; ]&nbsp;</TD>
    <TD align=left width="25%">Accelerated filer </TD>
    <TD align=left width="25%">[&nbsp;&nbsp; ]&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="25%">&nbsp; </TD>
    <TD width="25%">&nbsp; </TD>
    <TD width="25%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Non-accelerated filer </TD>
    <TD align=left width="25%">[&nbsp;&nbsp; ]&nbsp;</TD>
    <TD align=left width="25%">Smaller reporting company </TD>
    <TD align=left width="25%">[X]&nbsp;</TD></TR></TABLE><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-TOP: #000000 1px solid; BORDER-BOTTOM: #000000 3px double"
    align=center colSpan=5><B>CALCULATION OF REGISTRATION FEE</B>&nbsp; </TD></TR>
  <TR>
    <TD align=center>&nbsp; </TD>
    <TD style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid"
    align=center width="20%">&nbsp; </TD>
    <TD style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid"
    align=center width="20%">&nbsp; </TD>
    <TD style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid"
    align=center width="20%">&nbsp; </TD>
    <TD align=center width="20%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=center>&nbsp; </TD>
    <TD style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid"
    align=center width="20%">&nbsp; </TD>
    <TD style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid"
    align=center width="20%"><B>Proposed</B> </TD>
    <TD style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid"
    align=center width="20%"><B>Proposed</B> </TD>
    <TD align=center width="20%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=center>&nbsp; </TD>
    <TD style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid"
    align=center width="20%"><B>Amount</B> </TD>
    <TD style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid"
    align=center width="20%"><B>Maximum</B> </TD>
    <TD style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid"
    align=center width="20%"><B>Maximum</B> </TD>
    <TD align=center width="20%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=center><B>Title of Each Class of</B> </TD>
    <TD style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid"
    align=center width="20%"><B>to be</B> </TD>
    <TD style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid"
    align=center width="20%"><B>Offering Price</B> </TD>
    <TD style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid"
    align=center width="20%"><B>Aggregate</B> </TD>
    <TD align=center width="20%"><B>Amount of</B> </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center><B>Securities to
      be Registered</B> </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%"><B>Registered(1)</B> </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%"><B>Per Security(1)</B> </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%"><B>Offering Price(1)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="20%"><B>Registration Fee(2)</B> </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><B>Primary
      Offering By Anavex Life</B> <B>Sciences, Inc.</B> </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%"></TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%"></TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
  width="20%"></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid"
      align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Stock, par
      value $0.001 per share </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">(1) </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">(1) </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">$100,000,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="20%">(2)
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right>&nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Total for
      Primary Offering: </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">(1) </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">(1) </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">$100,000,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="20%">$10,070 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><B>Secondary
      Offering By Selling</B> <B>Security Holder</B> </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%"></TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%"></TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
  width="20%"></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid"
      align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Stock, par
      value $0.001 per share </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">(1) </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">(1) </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">$50,000,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="20%">(2)
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid"
      align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Stock, par
      value $0.001 per share </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">269,397 </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">- </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="20%">-
  </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right>&nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Total for Secondary Offering: </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">(1) </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">(1) </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"
    align=center width="20%">$50,000,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="20%">$5,035 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left><B>Total</B> </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 3px double"
    align=center width="20%">&nbsp; </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 3px double"
    align=center width="20%">&nbsp; </TD>
    <TD
    style="BORDER-RIGHT: #000000 1px solid; BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 3px double"
    align=center width="20%">$150,000,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=center
      width="20%">$15,105 </TD></TR></TABLE></DIV><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">(1) </TD>
    <TD>
      <P align=justify>Securities registered hereunder may be sold separately,
      together or as units with other securities registered hereunder. An
      indeterminate aggregate initial offering price or number of shares of common stock
      of Anavex Life Sciences Corp. is being registered as may from time to time
      be issued at currently indeterminable prices with an aggregate maximum
      offering price not to exceed $100,000,000. In addition, up to $50,000,000
      of shares of common stock may be sold from time to time pursuant to this
      registration statement by the selling security holder described herein,
      and up to 269,397 shares of Common Stock, 179,958 of which were issued as
      an initial commitment fee, and 89,799 of which are issuable as an
      additional commitment fee.</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">(2) </TD>
    <TD>
      <P align=justify>Calculated in accordance with Rule 457(o) under the
      Securities Act.</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>


<!--$$/page=-->
<A name="page_3"></A>
<P align=justify><B>The registrant hereby amends this registration statement on
such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this
registration statement shall thereafter become effective in accordance with
Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine. </B> </P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">

<!--$$/page=--><A name=page_4></A>
<P align=justify><font color="#FF0000"><B>The information in this prospectus is not complete and may
be changed. This prospectus is included in a registration statement that we
filed with the Securities and Exchange Commission. We may not sell these
securities or accept an offer to buy these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This
prospectus is not an offer to sell these securities, and it is not soliciting
offers to buy these securities in any state where such offer or sale is not
permitted. </B></font></P>
<P align=center><font color="#FF0000"><B>SUBJECT TO COMPLETION, DATED OCTOBER __, 2015</B>
</font>
<BR><B>PROSPECTUS</B> </P>
<P align=center><B>Anavex Life Sciences Corp. </B></P>
<P align=center><B>$100,000,000 of Shares of Common Stock </B></P>
<P align=center><B>$50,000,000 of Shares of Common Stock and 269,397 Shares of
Common Stock Offered by Selling Security Holder</B></P>
<P align=justify style="text-indent:5%">Anavex Life Sciences Corp., a
Nevada corporation (&#147;<U>us</U>&#148;, &#147;<U>we</U>&#148;, &#147;<U>our</U>&#148;, &#147;<U>Anavex</U>&#148; or
the &#147;<U>Company</U>&#148;) may offer and sell from time to time, in one or more
series or issuances and on terms that Anavex will determine at the time of the
offering, shares of our common stock, par value $0.001 per share (&#147;<U>Common
Stock</U>&#148;) described in this prospectus, up to an aggregate amount of
$100,000,000.</P>
<P align=justify style="text-indent:5%">This prospectus also covers the
resale by Lincoln Park Capital Fund, LLC (&#147;<U>Lincoln Park</U>&#148; or the
&#147;<U>Selling</U> <U>Security Holder</U>&#148;), of up to an aggregate of $50,000,000
of shares of our Common Stock in one or more transactions in amounts, at prices,
and on terms that will be determined at the time these securities are offered,
and 269,397 shares of Common Stock issued or issuable to the Selling Security
Holder as commitment shares, as described in further detail herein. </P>
<P align=justify style="text-indent:5%"> We will not receive any of the
proceeds from the sale of shares of our Common Stock sold by the Selling
Security Holder. The Selling Security Holder may sell the shares of Common Stock
described in this prospectus in a number of different ways and at varying
prices. See &#147;Plan of Distribution&#148; for more information about how the Selling
Security Holder may sell the shares of Common Stock being registered pursuant to
this prospectus. The Selling Security Holder is an &ldquo;underwriter&rdquo; within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the &ldquo;<u>Securities Act</u>&rdquo;).</P>
<P align=justify style="text-indent:5%">This prospectus provides you with
a general description of the securities offered. We will file prospectus
supplements and may provide other offering material at later dates that will
contain specific terms of each offering of securities by us. These supplements
may also add, update or change information contained in this prospectus.</P>
<P align=justify style="text-indent:5%">You should read this prospectus
and the applicable prospectus supplement carefully before you invest in the
securities described in the applicable prospectus supplement. This prospectus
may not be used to consummate sales of securities unless accompanied by a
prospectus supplement.</P>
<P align=justify style="text-indent:5%">We will sell these securities
directly to our stockholders or to other purchasers or through agents on our
behalf or through underwriters or dealers as designated from time to time. If
any agents or underwriters are involved in the sale of any of these securities,
the applicable prospectus supplement will provide the names of the agents or
underwriters and any applicable fees, commission or discounts.</P>
<P align=justify style="text-indent:5%">Our common stock is currently
quoted on the OTC Markets - OTCQX under the symbol &#147;AVXLD&#148;. On October 21, 2015,
the last reported sale price of our common stock was $8.94 per share. </P>
<P align=justify style="text-indent:5%"><B>Investing in our securities
involves a high degree of risk. See the section entitled &#147;Risk Factors&#148; on page
5 of this prospectus and in the documents we filed with the Securities and
Exchange Commission that are incorporated in this prospectus by reference for
certain risks and uncertainties you should consider. </B></P>
<P align=center>i</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<P align=justify style="text-indent:5%"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or
disapproved of these securities or passed upon the adequacy or accuracy of this
prospectus. Any representation to the contrary is a criminal offense. </B></P>
<hr noshade align="center" width="100%" size=1 color="black">
<P align=center><b>This prospectus is dated October __, 2015. </b></P>
<hr noshade align="center" width="100%" size=1 color="black">
<P align=center>&nbsp;</P>
<P align=center>ii </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_5></A>
<P align=center>&nbsp;</P>
<P align=center><B>TABLE OF CONTENTS </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_6">ABOUT
      THIS PROSPECTUS </A></TD>
    <TD align=right width="15%" bgColor=#eeeeee><A
      href="#page_6">1
      </A></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_6">PROSPECTUS
      SUMMARY </A></TD>
    <TD align=right width="15%" bgColor=#eeeeee><A
      href="#page_6">1
      </A></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_11">SELECTED
      FINANCIAL DATA </A></TD>
    <TD align=right width="15%" bgColor=#eeeeee><A
      href="#page_11">6
      </A></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_12">RISK
      FACTORS </A></TD>
    <TD align=right width="15%" bgColor=#eeeeee><A
      href="#page_12">7
      </A></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_12">DOCUMENTS
      INCORPORATED BY REFERENCE </A></TD>
    <TD align=right width="15%" bgColor=#eeeeee><A
      href="#page_12">7
      </A></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_13">CAUTIONARY
      NOTE REGARDING FORWARD-LOOKING STATEMENTS </A></TD>
    <TD align=right width="15%" bgColor=#eeeeee><A
      href="#page_13">8
      </A></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_13">USE
      OF PROCEEDS </A></TD>
    <TD align=right width="15%" bgColor=#eeeeee><A
      href="#page_13">8
      </A></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_13">PLAN
      OF DISTRIBUTION </A></TD>
    <TD align=right width="15%" bgColor=#eeeeee><A
      href="#page_13">8
      </A></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_23a">DESCRIPTION
      OF OUR CAPITAL STOCK </A></TD>
    <TD align=right width="15%" bgColor=#eeeeee><A
      href="#page_23a">16</A></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_23a">LEGAL
      MATTERS </A></TD>
    <TD align=right width="15%" bgColor=#eeeeee><A
      href="#page_23a">16</A></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_23a">EXPERTS
      </A></TD>
    <TD align=right width="15%" bgColor=#eeeeee><A
      href="#page_23a">16</A></TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_19">DISCLOSURE
      OF COMMISSION POSITION ON INDEMNIFICATION </A></TD>
    <TD align=right width="15%" bgColor=#eeeeee><A
      href="#page_19">17</A></TD>
  </TR></TABLE>
<P align=center>iii </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_6></A>
<P align=center><B>ABOUT THIS PROSPECTUS </B></P>
<P align=justify style="text-indent:5%">This prospectus of Anavex Life
Sciences Corp., a Nevada corporation (collectively with all of its subsidiaries,
the &#147;Company&#148;, &#147;Anavex&#148;, or &#147;we&#148;, &#147;us&#148;, or &#147;our&#148;) is a part of a registration
statement that we filed with the Securities and Exchange Commission
(&#147;<U>SEC</U>&#148;) utilizing a &#147;shelf&#148; registration process. Under this shelf
registration process, we may, from time to time, sell the securities described
in this prospectus in one or more offerings. In addition, Lincoln Park may, from
time to time, offer and sell up to an aggregate of $50,000,000 of shares of our
Common Stock in one or more transactions, or an additional 269,397 shares of
Common Stock.</P>
<P align=justify style="text-indent:5%">The registration statement
containing this prospectus, including the exhibits to the registration
statement, provides additional information about us and the securities offered
under this prospectus. The registration statement, including the exhibits and
the documents incorporated herein by reference, can be read on the SEC website
or at the SEC offices mentioned under the heading &#147;Prospectus Summary - Where
You Can Find More Information.&#148; </P>
<P align=justify style="text-indent:5%">We may provide a prospectus supplement
  containing specific information about the amounts, prices and terms of the
  securities for a particular offering. The prospectus supplement may add, update
  or change information in this prospectus. If the information in the prospectus
  is inconsistent with a prospectus supplement, you should rely on the information
  in that prospectus supplement. You should read both this prospectus and, if
  applicable, any prospectus supplement. See &#147;Prospectus Summary - Where You Can
  Find More Information&#148; for more information. </P>
<P align=justify style="text-indent:5%">We have not authorized any
dealer, salesman or other person to give any information or to make any
representation other than those contained or incorporated by reference in this
prospectus or any prospectus supplement. You must not rely upon any information
or representation not contained or incorporated by reference in this prospectus
or any prospectus supplement. This prospectus and any prospectus supplement do
not constitute an offer to sell or the solicitation of an offer to buy any
securities other than the registered securities to which they relate, nor do
this prospectus and any prospectus supplement constitute an offer to sell or the
solicitation of an offer to buy securities in any jurisdiction to any person to
whom it is unlawful to make such offer or solicitation in such jurisdiction. You
should not assume that the information contained in this prospectus or any
prospectus supplement is accurate on any date subsequent to the date set forth
on the front of such document or that any information we have incorporated by
reference is correct on any date subsequent to the date of the document
incorporated by reference, even though this prospectus and any prospectus
supplement is delivered or securities are sold on a later date. </P>
<P align=center><B>PROSPECTUS SUMMARY </B></P>
<P align=justify><B><I>The items in the following summary are described in more
detail later in this prospectus. This summary does not contain all of the
information you should consider. Before investing in our securities, you should
read the entire prospectus carefully, including the &#147;Risk Factors&#148; beginning on
page 6 and the financial statements incorporated by reference. </I></B></P>
<P align=center><B>Overview</B></P>
<P align=justify><B><I>Our Current Business</I></B> </P>
<P align=justify style="text-indent:5%">We are a clinical stage
biopharmaceutical company engaged in the development of drug candidates to treat
Alzheimer&#146;s disease, other central nervous system (CNS) diseases, and various
types of cancer. Our lead compounds ANAVEX 2-73 and ANAVEX PLUS, a combination
of ANAVEX 2-73 with donepezil (Aricept), are being developed to treat
Alzheimer&#146;s disease and potentially other central nervous system (CNS) diseases.
</P>
<P align=justify style="text-indent:5%">In December 2014 a Phase 2a
clinical trial was initiated for ANAVEX 2-73, which is being evaluated for the
treatment of Alzheimer&#146;s disease. The randomized trial is designed to assess the
safety and exploratory efficacy of ANAVEX 2-73 alone as well as in combination
with donepezil (ANAVEX PLUS) in patients with mild to moderate Alzheimer&#146;s
disease. ANAVEX 2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in
the brain and to reverse the pathological hallmarks observed in Alzheimer&#146;s
disease. ANAVEX 2-73 showed no serious adverse events in a previously performed
Phase 1 study. In pre-clinical studies, ANAVEX 2-73 demonstrated anti-amnesic
and neuroprotective properties in various animal models including the transgenic
mouse model Tg2576. </P>
<P align=center>1 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_7></A>
<P align=justify style="text-indent:5%">We intend to identify and
initiate discussions with potential partners in the next 12 months. Further, we
may acquire or develop new intellectual property and assign, license, or
otherwise transfer our intellectual property to further our goals. </P>
<P align=justify><B><I>Our Pipeline</I></B> </P>
<P align=justify style="text-indent:5%">Our pipeline includes one
clinical drug candidate and several compounds in different stages of
pre-clinical study. </P>
<P align=justify style="text-indent:5%">Our proprietary SIGMACEPTOR&#153;
Discovery Platform produced small molecule drug candidates with unique modes of
action, based on our understanding of sigma receptors. Sigma receptors may be
targets for therapeutics to combat many human diseases, including Alzheimer&#146;s
disease. When bound by the appropriate ligands, sigma receptors influence the
functioning of multiple biochemical signals that are involved in the
pathogenesis (origin or development) of disease. </P>
<P align=justify style="text-indent:5%">Compounds that have been subjects of our research include the
following: </P>
<P align=justify style="text-indent:5%"><B>ANAVEX 2-73</B> </P>
<P align=justify style="text-indent:5%">ANAVEX 2-73 may offer a
disease-modifying approach in Alzheimer&#146;s disease (AD) by using ligands that
activate sigma-1 receptors. </P>
<P align=justify style="text-indent:5%">In AD animal models, ANAVEX 2-73
has shown pharmacological, histological and behavioral evidence as a potential
neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic
agent, due to its potent affinity to sigma-1 receptors and moderate affinities
to M1-4 type muscarinic receptors. In addition, ANAVEX 2-73 has shown a
potential dual mechanism which may impact both amyloid and tau pathology. In a
transgenic AD animal model Tg2576 ANAVEX 2-73 induced a statistically
significant neuroprotective effect against the development of oxidative stress
in the mouse brain, as well as significantly increased the expression of
functional and synaptic plasticity markers that is apparently amyloid-beta
independent. It also statistically alleviated the learning and memory deficits
developed over time in the animals, regardless of sex, both in terms of spatial
working memory and long-term spatial reference memory. </P>
<P align=justify style="text-indent:5%">Based on the results of
pre-clinical testing, we initiated and completed a Phase 1 single ascending dose
(SAD) clinical trial of ANAVEX 2-73 in 2011. In this Phase 1 SAD trial, the
maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is
above the equivalent dose shown to have positive effects in mouse models of AD.
There were no significant changes in laboratory or electrocardiogram (ECG)
parameters. ANAVEX 2-73 was well tolerated below the 55-60 mg dose with only
mild adverse events in some subjects. Observed adverse events at doses above the
maximum tolerated single dose included headache and dizziness, which were
moderate in severity and reversible. These side effects are often seen with
drugs that target central nervous system (CNS) conditions, including AD. </P>
<P align=justify style="text-indent:5%">The ANAVEX 2-73 Phase 1 SAD trial
was conducted as a randomized, placebo-controlled study. Healthy male volunteers
between the ages of 18 and 55 received single, ascending oral doses over the
course of the trial. Study endpoints included safety and tolerability together
with pharmacokinetic parameters. Pharmacokinetics includes the absorption and
distribution of a drug, the rate at which a drug enters the blood and the
duration of its effect, as well as chemical changes of the substance in the
body. This study was conducted in Germany in collaboration with ABX-CRO, a
clinical research organization that has conducted several Alzheimer&#146;s disease
studies, and the Technical University of Dresden. </P>
<P align=justify style="text-indent:5%">As well, recent preclinical data
validates ANAVEX 2-73 as a prospective platform drug for other neurodegenerative
diseases beyond Alzheimer&#146;s, most specifically epilepsy. The data demonstrates
significant improvement in the reduction of seizures relative to three
generations of epilepsy drugs currently on the market, as well as significant
synergy with each of these drugs. </P>
<P align=center>2 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_8></A>
<P align=justify style="text-indent:5%"><B>ANAVEX PLUS</B> </P>
<P align=justify style="text-indent:5%">ANAVEX PLUS, a combination of
ANAVEX 2-73 with donepezil (Aricept&#174;) is a potential novel combination drug for
Alzheimer&#146;s disease. Aricept&#174; (donepezil) is now generic. ANAVEX 2-73 showed in
combination with donepezil an unexpected and clear synergic effect of memory
improvement by up to 80% in animal models. A patent application was filed in the
US for the combination of donepezil and ANAVEX 2-73 and if granted would give
patent protection at least until 2033. </P>
<P align=justify style="text-indent:5%">In a humanized calibrated
cortical network computer model the unexpected pre-clinical synergy between
ANAVEX 2-73 and donepezil was confirmed and ANAVEX PLUS showed an anticipated
ADAS-Cog response of 7 points at 12 weeks and 5.5 points at 26 weeks, which
represents more than 2x the ADAS-Cog of donepezil alone. </P>
<P align=justify style="text-indent:5%"><B>ANAVEX 3-71</B> </P>
<P align=justify style="text-indent:5%">ANAVEX 3-71, previously named
AF710B is a preclinical drug candidate with a novel mechanism of action via
sigma-1 receptor activation and M1 muscarinic allosteric modulation, which has
shown to enhance neuroprotection and cognition in Alzheimer's disease. ANAVEX
3-71 is a CNS-penetrable mono-therapy that bridges treatment of both cognitive
impairments with disease modifications. It is highly effective in very small
doses against the major Alzheimer's hallmarks in transgenic (3xTg-AD) mice,
including cognitive deficits, amyloid and tau pathologies, and also has
beneficial effects on inflammation and mitochondrial dysfunctions. ANAVEX 3-71
indicates extensive therapeutic advantages in Alzheimer's and other
protein-aggregation-related diseases given its ability to enhance
neuroprotection and cognition via sigma-1 receptor activation and M1 muscarinic
allosteric modulation. </P>
<P align=justify style="text-indent:5%"><B>ANAVEX 1-41</B> </P>
<P align=justify style="text-indent:5%">ANAVEX 1-41 is a sigma-1 agonist.
Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects
nerve cells from degeneration or death) through the modulation of endoplasmic
reticulum, mitochondrial and oxidative stress, which damages and destroys cells
and is believed by some scientists to be a primary cause of AD. In addition, in
animal models, ANAVEX 1-41 prevented the expression of caspase-3, an enzyme that
plays a key role in apoptosis (programmed cell death) and loss of cells in the
hippocampus, the part of the brain that regulates learning, emotion and memory.
These activities involve both muscarinic and sigma-1 receptor systems through a
novel mechanism of action. </P>
<P align=justify style="text-indent:5%"><B>ANAVEX 1037</B> </P>
<P align=justify style="text-indent:5%">ANAVEX 1037 is designed for the
treatment of prostate cancer. It is a low molecular weight, synthetic compound
exhibiting high affinity for sigma-1 receptors at nanomolar levels and moderate
affinity for sigma-2 receptors and sodium channels at micromolar levels. In
advanced pre-clinical studies, this compound revealed antitumor potential with
no toxic side effects. It has also been shown to selectively kill human cancer
cells without affecting normal/healthy cells and also to significantly suppress
tumor growth in immune-deficient mice models. Scientific publications describe
sigma receptor ligands positively, highlighting the possibility that these
ligands may stop tumor growth and induce selective cell death in various tumor
cell lines. Sigma receptors are highly expressed in different tumor cell types.
Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective
apoptosis. In addition, through tumor cell membrane reorganization and
interactions with ion channels, our drug candidates may play an important role
in inhibiting the processes of metastasis (spreading of cancer cells from the
original site to other parts of the body), angiogenesis (the formation of new
blood vessels) and tumor cell proliferation. </P>
<P align=justify style="text-indent:5%">Our compounds are in the
pre-clinical and clinical testing stages of development, and there is no
guarantee that the activity demonstrated in pre-clinical models will be shown in
human testing. </P>
<P align=justify><B><I>Our Target Indications</I></B> </P>
<P align=justify style="text-indent:5%">We have developed compounds with
potential application to two broad categories and several specific indications.
The two categories are diseases of the central nervous system, and cancer.
Specific indications include: </P>
<P align=center>3 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_9></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left  >&#149; </TD>
    <TD align=left width="95%">
      <P align=justify>Alzheimer&#146;s disease &#150; In 2014, an estimated 5.2 million
      Americans are suffering from Alzheimer&#146;s disease. The Alzheimer&#146;s
      Association&#174; reports that by 2025, 7.1 million Americans will be afflicted
      by the disease, a 40 percent increase from currently affected patients.
      Medications on the market today treat only the symptoms of AD and do not
      have the ability to stop its onset or its progression. There is an urgent
      and unmet need for both a disease modifying cure for Alzheimer&#146;s disease
      as well as for better symptomatic treatments. </P></TD></TR>
  <TR>
    <TD  >&nbsp;</TD>
    <TD width="95%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left  >&#149; </TD>
    <TD align=left width="95%">
      <P align=justify>Depression - Depression is a major cause of morbidity
      worldwide according to the World Health Organization (WHO). Pharmaceutical
      treatment for depression is dominated by blockbuster brands, with the
      leading nine brands accounting for approximately 75% of total sales.
      However, the dominance of the leading brands is waning, largely due to the
      effects of patent expiration and generic competition. Our market research
      leads us to believe that the worldwide market for pharmaceutical treatment
      of depression exceeds $11 billion annually. </P></TD></TR>
  <TR>
    <TD  >&nbsp;</TD>
    <TD width="95%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left  >&#149; </TD>
    <TD align=left width="95%">
      <P align=justify>Epilepsy - Epilepsy is a common chronic neurological
      disorder characterized by recurrent unprovoked seizures. These seizures
      are transient signs and/or symptoms of abnormal, excessive or synchronous
      neuronal activity in the brain. According to the Centers for Disease
      Control and Prevention, epilepsy affects 2.2 million Americans. Today,
      epilepsy is often controlled, but not cured, with medication that is
      categorized as older traditional anti-epileptic drugs and second
      generation anti epileptic drugs. Because epilepsy afflicts sufferers in
      different ways, there is a need for drugs used in combination with both
      traditional anti-epileptic drugs and second generation anti- epileptic
      drugs. Decision Resources, one of the world&#146;s leading research and
      advisory firms for pharmaceutical and healthcare issues, finds that the
      epilepsy market will increase from $2.9 billion in 2011 to nearly $3.7
      billion in 2016. </P></TD></TR>
  <TR>
    <TD  >&nbsp;</TD>
    <TD width="95%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left  >&#149; </TD>
    <TD align=left width="95%">
      <P align=justify>Neuropathic Pain &#150; We define neuralgia, or neuropathic
      pain, as pain that is not related to activation of pain receptor cells in
      any part of the body. Neuralgia is more difficult to treat than some other
      types of pain because it does not respond well to normal pain medications.
      Special medications have become more specific to neuralgia and typically
      fall under the category of membrane stabilizing drugs or antidepressants.
      Our market research leads us to believe the worldwide market for
      pharmaceutical treatment of neuropathic pain exceeds $5 billion annually.
      </P></TD></TR>
  <TR>
    <TD  >&nbsp;</TD>
    <TD width="95%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left  >&#149; </TD>
    <TD align=left width="95%">
      <P align=justify>Malignant Melanoma - Predominantly a skin cancer,
      malignant melanoma can also occur in melanocytes found in the bowel and
      the eye. Malignant melanoma accounts for 75% of all deaths associated with
      skin cancer. The treatment includes surgical removal of the tumor,
      adjuvant treatment, chemo and immunotherapy, or radiation therapy.
      According to IMS Health the worldwide Malignant Melanoma market is
      expected to grow from about $900 million in 2012 to $4.4 billion by 2022.
      </P></TD></TR>
  <TR>
    <TD  >&nbsp;</TD>
    <TD width="95%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left  >&#149; </TD>
    <TD align=left width="95%">
      <P align=justify>Prostate Cancer &#150; Specific to men, prostate cancer is a
      form of cancer that develops in the prostate, a gland in the male
      reproductive system. The cancer cells may metastasize from the prostate to
      other parts of the body, particularly the bones and lymph nodes. Drug
      therapeutics for Prostate Cancer are expected to increase from $8.1
      billion in 2012 to nearly $18.6 billion in 2017 according to BCC Research.
      </P></TD></TR>
  <TR>
    <TD  >&nbsp;</TD>
    <TD width="95%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left  >&#149; </TD>
    <TD align=left width="95%">
      <P align=justify>Pancreatic Cancer - Pancreatic cancer is a malignant
      neoplasm of the pancreas. In the United States approximately 45,000 new
      cases of pancreatic cancer will be diagnosed this year and approximately
      38,000 patients will die as a result of their cancer. Our market research
      leads us to believe that the market for the pharmaceutical treatment of
      pancreatic cancer will exceed $1.2 billion in 2015.
</P></TD></TR></TABLE>
<P align=justify><B>Corporate Information</B></P>
<P align=justify style="text-indent:5%">Our principal executive office is
located at 51 West 52nd Street, 7th Floor, New York, NY 10019-6163, and our
telephone number is 844.689.3939. Our website address is <U>www.anavex.com</U>.
No information found on our website is part of this prospectus. Also, this
prospectus may include the names of various government agencies or the trade
names of other companies. Unless specifically stated otherwise, the use or
display by us of such other parties&#146; names and trade names in this prospectus is
not intended to and does not imply a relationship with, or endorsement or
sponsorship of us by, any of these other parties.</P>
<P align=center>4 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_10></A>
<P align=justify><B>The Offerings </B></P>
<P align=justify style="text-indent:5%">We may offer and sell, from time to time, in one or more offerings, the securities that we describe in this prospectus having a total initial offering price not exceeding $100,000,000 at prices and on terms to be determined by market conditions at the time of any offering. </P>
<P align=justify style="text-indent:5%">On October 21, 2015, the Company entered into a purchase agreement (the &ldquo;<u>Purchase Agreement</u>&rdquo;) with the Selling Security Holder (such transaction, the &ldquo;<u>Financing</u>&rdquo;), pursuant to which the Selling Security Holder agreed to purchase from us up to $50,000,000 of our Common Stock (subject to certain limitations) from time to time over a 36-month period. In connection with the Financing, the Company also entered into a registration rights agreement with the Selling Security Holder (the &ldquo;<u>RRA</u>&rdquo;) whereby the Company agreed to file a registration statement, of which this prospectus is a part, with the U.S. Securities and Exchange Commission (&ldquo;<u>SEC</u>&rdquo;) covering the shares of the Company&rsquo;s Common Stock that may be issued to the Selling Security Holder under the Purchase Agreement. </P>
<P align=justify style="text-indent:5%">After the registration statement, of which this prospectus is a part, is declared effective, the Company may, from time to time and at its sole discretion, direct the Selling Security Holder to purchase up to 50,000 shares of our Common Stock on any such business day, provided that in no event shall the Selling Security Holder purchase more than $2,000,000 worth of our common stock on any single business day, plus an additional &ldquo;accelerated amount&rdquo; under certain circumstances. Except as described in this prospectus, there are no trading volume requirements or restrictions under the Purchase Agreement, and we will control the timing and amount of any sales of our Common Stock to the Selling Security Holder. The purchase price of the up to 50,000 shares that may be sold to the Selling Security Holder under the Purchase Agreement on any business day will be based on the market price of our common stock immediately preceding the time of sale as computed under the Purchase Agreement without any fixed discount. The purchase price per share will be equitably adjusted for any reorganization, recapitalization, non-cash dividend, forward or reverse stock split, or other similar transaction occurring during the business days used to compute such price. We may at any time in our sole discretion terminate the Purchase Agreement without fee, penalty or cost upon one business day&rsquo;s notice. The Selling Security </P>
<P align=justify style="text-indent:5%">The Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification and termination provisions by, among and for the benefit of the parties. The Selling Security Holder has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company&rsquo;s common stock. </P>
<P align=justify style="text-indent:5%">In consideration for entering into the Purchase Agreement, the
Company issued to the Selling Security Holder, 179,598 shares of Common Stock as
a commitment fee and shall issue up to 89,799 shares pro rata, which commitment
fee shares are also being registered hereunder, when and if, the Selling
Security Holder purchases at the Company&#146;s discretion the $50,000,000 aggregate
commitment. The Purchase Agreement may be terminated by the Company at any time
at its discretion without any cost to the Company.</P>
<P align=justify style="text-indent:5%">This prospectus provides you with
a general description of the securities us and the Selling Security Holder may
offer. Each time we offer a type or series of securities under this prospectus,
we will provide a prospectus supplement that will describe the specific amounts,
prices and other important terms of the securities. </P>
<P align=justify style="text-indent:5%">The prospectus supplement also
may add, update or change information contained in this prospectus or in
documents we have incorporated by reference into this prospectus. However, no
prospectus supplement will fundamentally change the terms that are set forth in
this prospectus or offer a security that is not registered and described in this
prospectus at the time of its effectiveness. </P>
<P align=justify><B>Where You Can Find More Information </B></P>
<P align=justify style="text-indent:5%">We are subject to the information
requirements of the Securities Exchange Act of 1934 (the &#147;<U>Exchange</U>
<U>Act</U>&#148;). Accordingly, we file annual, quarterly and current reports, proxy
statements as may be required and other information with the SEC and filed a
registration statement on Form S-3 under the Securities Act relating to the
securities offered by this prospectus. This prospectus, which forms part of the
registration statement, does not contain all of the information included in the
registration statement. For further information, you should refer to the
registration statement and its exhibits. </P>
<P align=justify style="text-indent:5%">You may read and copy the
registration statement and any document we file with the SEC at the SEC&#146;s Public
Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the
SEC at 1-800-SEC-0330 for further information on the operation of the Public
Reference Room. You can also review our filings by accessing the website
maintained by the SEC at <U>http://www.sec.gov</U>. The site contains reports,
proxy and information statements and other information regarding issuers that
file electronically with the SEC. In addition to the foregoing, we maintain a
website at http://www.anavex.com. Our website content is made available for
informational purposes only. It should neither be relied upon for investment
purposes nor is it incorporated by reference into this prospectus. We make
available at <U>http://www.anavex.com/investors/share-data/</U> copies of our
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K and any amendments to such document as soon as practicable after we
electronically file such material with or furnish such documents to the SEC.</P>
<P align=center>5 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_11></A>
<P align=center><B>SELECTED FINANCIAL DATA </B></P>
<P align=justify style="text-indent:5%">The following selected financial
data should be read in conjunction with our financial statements and the related
notes contained in Item 8 of Part II of our Annual Report on Form 10-K for the
fiscal year ended September 30, 2014 and our interim consolidated financial
statements and the related notes contained in Item 1 of Part I of our Quarterly
Report on Form 10-Q for the quarter ended June 30, 2015, which are incorporated
by reference into this prospectus, except that share and per share information
for the years ended September 30, 2014 and 2013 and for the nine months ended
June 30, 2015 and 2014 have been revised to reflect the reverse stock split of
our issued and outstanding shares of common stock effective on October 7, 2015,
at a ratio of 1 to 4. The selected data in this section is not intended to
replace such financial statements, except that share and per share information
has been revised for the periods presented to reflect the reverse stock split at
a ratio of 1 to 4. </P>
<P align=justify style="text-indent:5%">We have derived the statements of
operations data for each of the years ended September 30, 2014 and 2013 and the
balance sheet data as of September 30, 2014 and 2013 from the audited
consolidated financial statements contained in Item 8 of Part II of our Annual
Report on Form 10-K for the year ended September 30, 2014. The consolidated
statement of operations data set forth below for the nine months ended June 30,
2015 and 2014 and the consolidated balance sheet data as of June 30, 2015 has
been derived from our consolidated financial statements included in Item 1 of
Part I of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2015,
which is incorporated by reference into this prospectus. </P>
<P align=justify style="text-indent:5%">The historical financial
information set forth below may not be indicative of our future performance and
should be read together with &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations&#148; and our historical consolidated financial
statements and notes to those statements included in Item 7 of Part II and Item
8 of Part II, respectively, of our Annual Report on Form 10-K for the year ended
September 30, 2014, &#147;Management&#146;s Discussion and Analysis of Financial Condition
and Results of Operations&#148; and our historical financial statements and notes to
those statements included in Item 2 of Part I and Item 1 of Part I,
respectively, of our Quarterly Report on Form 10-Q for the quarter ended June
30, 2015, and update thereto reflected in subsequent filings with the SEC, and
all other annual, quarterly and other reports that we file with the SEC after
the date of this prospectus and that also are incorporated herein by reference.
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD vAlign=bottom noWrap align=left>&nbsp; </TD>
    <TD vAlign=bottom noWrap align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="27%" colSpan=4><B>Nine months
      ended June 30,</B> </TD>
    <TD vAlign=bottom noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom noWrap align=left>&nbsp; </TD>
    <TD vAlign=bottom noWrap align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="12%"><B>2015</B> </TD>
    <TD vAlign=bottom noWrap align=center width="2%" >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%" >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="12%"><B>2014</B> </TD>
    <TD vAlign=bottom noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom noWrap align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="12%"><B>(unaudited)</B> </TD>
    <TD vAlign=bottom noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap align=center
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="12%"><B>(unaudited)</B> </TD>
    <TD vAlign=bottom noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left bgColor=#e6efff>Research and development
      expenses </TD>
    <TD vAlign=bottom align=left width="1%"
      bgColor=#e6efff><B>$</B></TD>
    <TD vAlign=bottom align=right width="12%"
      bgColor=#e6efff><B>&nbsp;</B>1,525,233 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
      bgColor=#e6efff><B>$</B></TD>
    <TD vAlign=bottom align=right width="12%"
      bgColor=#e6efff><B>&nbsp;</B>388,347 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>General and administrative expenses </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">1,616,744 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">1,941,261 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left bgColor=#e6efff>Net loss </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(6,751,821</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)
</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(1,669,313 </TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)
  </TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>Net loss per share, basic and diluted </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(0.44</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(0.17</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left bgColor=#e6efff>Weighted average number of
      common shares, basic and diluted </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>15,438,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>9,554,560 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD vAlign=bottom noWrap align=left>&nbsp; </TD>
    <TD vAlign=bottom noWrap align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="27%" colSpan=4><B>Year ended
      September 30,</B> </TD>
    <TD vAlign=bottom noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom noWrap align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="12%"><B>2014</B> </TD>
    <TD vAlign=bottom noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="12%"><B>2013</B> </TD>
    <TD vAlign=bottom noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left bgColor=#e6efff>Research and development
      expenses </TD>
    <TD vAlign=bottom align=left width="1%"
      bgColor=#e6efff><B>$</B></TD>
    <TD vAlign=bottom align=right width="12%"
      bgColor=#e6efff><B>&nbsp;</B>732,395 <B>$</B> </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>263,847 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>&nbsp; </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">1,873,52 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left bgColor=#e6efff>General and administrative
      expenses </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>2,236,580 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>0 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>Net loss </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(11,368,353</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(3,700,046</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left bgColor=#e6efff>Net loss per share </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>&nbsp; &nbsp;Basic </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(1.14</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(0.46</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left bgColor=#e6efff>&nbsp; &nbsp;Diluted </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(1.21</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)
</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(0.46</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)
  </TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>&nbsp; </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">7,977,11 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left bgColor=#e6efff>Weighted average number of
      common shares, basic and diluted </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>9,931,933 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>1 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P align=center>6 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_12></A>
<P align=justify><B>Selected Balance Sheet Data </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD vAlign=bottom noWrap align=left>&nbsp; </TD>
    <TD vAlign=bottom noWrap align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="10%"><B>At June 30,</B> </TD>
    <TD vAlign=bottom noWrap align=center width="2%" >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%" >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="23%" colSpan=4><B>At
      September 30,</B> </TD>
    <TD vAlign=bottom noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom noWrap align=left>&nbsp; </TD>
    <TD vAlign=bottom noWrap align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="10%"><B>2015</B> </TD>
    <TD vAlign=bottom noWrap align=center width="2%" >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%" >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="10%"><B>2014</B> </TD>
    <TD vAlign=bottom noWrap align=center width="2%" >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%" >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="10%"><B>2013</B> </TD>
    <TD vAlign=bottom noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom noWrap align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="10%"><B>(unaudited)</B> </TD>
    <TD vAlign=bottom noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="10%">&nbsp; </TD>
    <TD vAlign=bottom noWrap align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="10%">&nbsp; </TD>
    <TD vAlign=bottom noWrap align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left bgColor=#e6efff>Cash </TD>
    <TD vAlign=bottom align=left width="1%"
      bgColor=#e6efff><B>$</B></TD>
    <TD vAlign=bottom align=right width="10%"
      bgColor=#e6efff><B>&nbsp;</B>7,961,331 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
      bgColor=#e6efff><B>$</B></TD>
    <TD vAlign=bottom align=right width="10%"
      bgColor=#e6efff><B>&nbsp;</B>7,262,138 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
      bgColor=#e6efff><B>$</B></TD>
    <TD vAlign=bottom align=right width="10%"
      bgColor=#e6efff><B>&nbsp;</B>345,074 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>Working Capital (Deficit) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="10%">6,625,818 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="10%">5,910,106 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="10%">(1,559,211</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left bgColor=#e6efff>Total Assets </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="10%" bgColor=#e6efff>7,978,886 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="10%" bgColor=#e6efff>7,353,502 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="10%" bgColor=#e6efff>393,449 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>Long-term debt </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="10%">57,962 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="10%">263,727 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="10%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left bgColor=#e6efff>Total Stockholders&#146; Equity
      (Deficiency) </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="10%" bgColor=#e6efff>6,569,357 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="10%" bgColor=#e6efff>192,626 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="10%" bgColor=#e6efff>(2,463,211</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)
  </TD></TR></TABLE>
<P align=center><B>RISK FACTORS </B></P>
<P align=justify style="text-indent:5%">An investment in our securities which may be offered hereby is subject to numerous risks, including the risks described under the caption &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended September 30, 2014, which is incorporated by reference herein. You should carefully consider these risks, along with the information provided elsewhere in this prospectus and the documents we incorporate by reference in this prospectus before investing in our securities.  You could lose all or part of your investment in the securities. You should consider these matters in conjunction with the other information included or incorporated by reference in this prospectus. The risks and uncertainties described in this prospectus, any applicable prospectus supplement and the documents incorporated by reference herein are not the only ones facing us. Additional risks and uncertainties that we do not presently know about or that we currently believe are not material may also adversely affect our business. Our business, results of operations or financial condition could be seriously harmed, and the trading price of our common stock may decline due to any of these or other risks.</P>
<P align=justify style="text-indent:5%"><i>This prospectus contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements appear in a number of places in this prospectus and include statements regarding the intent, belief or current expectations of our management, directors or officers primarily with respect to our future operating performance. Prospective purchasers of our securities are cautioned that these forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those in the forward-looking statements due to various factors. The accompanying information contained in this prospectus, including the information set forth below, identifies important factors that could cause these differences. See &ldquo;Forward-Looking Statements&rdquo; below.</i></P>
<P align=justify><b>Risks Relating to the Purchase Agreement with the Selling Security Holder</b></P>
<P align=justify style="text-indent:5%"><b><i>The sale or issuance of our common stock to the Selling Security Holder  may cause dilution and the sale of the shares of common stock acquired by the Selling Security Holder, or the perception that such sales may occur, could cause the price of our common stock to fall.</i></b></P>
<P align=justify style="text-indent:5%">On October 21, 2015, we entered into the Purchase Agreement with the Selling Security Holder, pursuant to which the Selling Security Holder has committed to purchase up to $50,000,000 of our Common Stock. Concurrently with the execution of the Purchase Agreement on October 21, 2015, we issued 179,958 shares of our common stock to the Selling Security Holder as a fee for its commitment to purchase additional shares of our common stock under the Purchase Agreement. We have not issued additional shares of common stock to the Selling Security Holder since the execution of the Purchase Agreement. Additional purchase shares that may be sold pursuant to the Purchase Agreement may be sold by us to Lincoln Park at our discretion from time to time commencing after the SEC declares effective the registration statement that this prospectus forms a part, until October 2018. </P>
<P align=justify style="text-indent:5%">The purchase price for the shares that we may sell to the Selling Security Holder under the Purchase Agreement will fluctuate based on the price of our common stock. Depending on market liquidity at the time, sales of such shares may cause the trading price of our common stock to fall. </P>
<P align=justify style="text-indent:5%">We generally have the right to control the timing and amount of any sales of our shares to the Selling Security Holder. Sales of our Common Stock, if any, to the Selling Security Holder will depend upon market conditions and other factors to be determined by us. Therefore, the Selling Security Holder may ultimately purchase all, some or none of the shares of our Common Stock that may be sold pursuant to the Purchase Agreement and, after it has acquired shares, the Selling Security Holder may sell all, some or none of those shares. Sales to the Selling Security Holder by us could result in substantial dilution to the interests of other holders of our Common Stock. Additionally, the sale of a substantial number of shares of our Common Stock to the Selling Security Holder, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.</P>
<P align=center><B>DOCUMENTS INCORPORATED BY REFERENCE</B></P>
<P align=justify style="text-indent:5%">The SEC allows us to &#147;incorporate
by reference&#148; into this prospectus certain information that we file with the
SEC, which means that we can disclose important information to you by referring
you to other documents separately filed by us with the SEC that contain such
information. The information we incorporate by reference is considered to be
part of this prospectus and information we later file with the SEC will
automatically update and supersede the information in this prospectus. The
following documents filed by us with the SEC pursuant to Section 13(a) of the
Exchange Act and any of our future filings under Sections 13(a), 13(c), 14 or 15
(d) of the Exchange Act, except for information furnished under Item 2.02 or
7.01 of Current Report on Form 8-K, or exhibits related thereto, made before the
termination of the offering are incorporated by reference herein: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(1) </TD>
    <TD>
      <P align=justify>our Annual Report on Form 10-K for the fiscal year ended
      September 30, 2014, filed with the SEC on December 29, 2014;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(2) </TD>
    <TD>
      <P align=justify>our Quarterly Reports on Form 10-Q for the fiscal periods
      ended: (i) December 31, 2014, as filed with the SEC on February 17, 2015;
      (ii) March 31, 2015, as filed with the SEC on May 14, 2015; and (iii) June
      30, 2015, as filed with the SEC on August 14, 2015;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(3) </TD>
    <TD>
      <P align=justify>our Current Reports on Form 8-K, as filed with the SEC on
      October 23, 2014, December 12, 2014, March 30, 2015, May 29, 2015, June
      17, 2015, July 23, 2015, September 28, 2015, October 6, 2015 and October
      7, 2015;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(4) </TD>
    <TD>
      <P align=justify>all other reports filed pursuant to Section 13(a) or
      15(d) of the Exchange Act and all proxy or information statements filed
      pursuant to Section 14 of the Exchange Act since the end of the fiscal
      year covered by the Annual Report referenced in (1) above; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(5) </TD>
    <TD>
      <P align=justify>The description of our common stock contained in the
      Registration Statement on Form 8-A filed with the SEC on December 6,
      2005.</P></TD></TR></TABLE>
<P align=justify style="text-indent:5%">In addition, all documents
subsequently filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the
Exchange Act before the date our offering is terminated or complete are deemed
to be incorporated by reference into, and to be a part of, this prospectus. </P>
<P align=justify style="text-indent:5%">We will provide to each person,
including any beneficial owner, to whom a prospectus is delivered, a copy of any
or all of the reports or documents that have been incorporated by reference in
the prospectus contained in the registration statement but not delivered with
the prospectus, other than an exhibit to these filings unless we have
specifically incorporated that exhibit by reference into the filing, upon
written or oral request and at no cost to the requester. Requests should be made
by writing or telephoning us at the following address: </P>
<P align=center>7 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black noShade SIZE=5>
<!--$$/page=--><A name=page_13></A>
<P align=center>Anavex Life Sciences Corp. <BR>51 West 52nd Street, 7th Floor <BR>New York, NY 10019-6163
<BR>(844) 689-3939 </P>
<P align=center><B>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P align=justify style="text-indent:5%">This prospectus contains forward-looking statements within the
meaning of Section 27A of the Securities Act regarding our business, financial
condition, results of operations and prospects. Words such as &#147;expects&#148;,
&#147;anticipates&#148;, &#147;intends&#148;, &#147;plans&#148;, &#147;believes&#148;, &#147;seeks&#148;, &#147;estimates&#148; and similar
expressions or variations of such words are intended to identify forward-looking
statements. However, these are not the exclusive means of identifying
forward-looking statements. Although forward-looking statements contained in
this prospectus reflect our good faith judgment, such statements can only be
based on facts and factors currently known to us. Consequently, forward-looking
statements are inherently subject to risks and uncertainties, and actual
outcomes may differ materially from the results and outcomes discussed in the
forward-looking statements. Further information about the risks and
uncertainties that may impact us are described or incorporated by reference in
&#147;Risk Factors&#148; beginning on page 6. You should read that section carefully. You
should not place undue reliance on forward-looking statements, which speak only
as of the date of this prospectus. We undertake no obligation to update publicly
any forward-looking statements in order to reflect any event or circumstance
occurring after the date of this prospectus or currently unknown facts or
conditions or the occurrence of unanticipated events. </P>
<P align=center><B>USE OF PROCEEDS</B></P>
<P align=justify style="text-indent:5%">Unless otherwise specified in the applicable prospectus
supplement, we intend to use the net proceeds from the sale of the securities
described in this prospectus in connection with the primary offering for general
corporate and operations purposes and to fund our anticipated growth. The
applicable prospectus supplement will provide more details on the use of
proceeds of any specific offering. We retain broad discretion in determining how
we allocate the net proceeds received in connection with the primary offering.
However, we expect that such cash will be used to further our business plan of
advancing human clinical trials of AVAVEX 2-73 and for general corporate and
administrative purposes.</P>
<P align=justify style="text-indent:5%">We will not receive any proceeds from the sale of shares of our
Common Stock by the Selling Security Holder named in such prospectus supplement.
</P>
<P align=center><B>PLAN OF DISTRIBUTION</B></P>
<P align=justify><I>Primary Offering </I></P>
<P align=justify style="text-indent:5%">We may sell the securities described in this prospectus on a
continuous or delayed basis directly to purchasers, through underwriters,
broker-dealers or agents that may receive compensation in the form of discounts,
concessions or commissions from us or the purchasers of the securities, in &#147;at
the market offerings&#148; within the meaning of Rule 415(a)(4) of the Securities
Act, to or through a market maker or into an existing trading market, on an
exchange, or otherwise or through a combination of any such methods of sale.
Discounts, concessions or commissions as to any particular underwriter,
broker-dealer or agent may be in excess of those customary in the types of
transactions involved. </P>
<P align=justify style="text-indent:5%">The securities may be sold from time to time in one or more
transactions at fixed prices, which may be changed from time to time, at
prevailing market prices at the time of sale, at varying prices determined at
the time of sale or at negotiated prices. These sales may be effected in
transactions, which may involve crosses or block transactions: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="5%"  ></TD>
    <TD align=left  >&#149; </TD>
    <TD align=justify width="90%">on any national securities exchange or
      quotation service on which the securities may be listed or quoted at the
      time of sale; </TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left  >&#149;</TD>
    <TD align=left width="90%">in the over-the-counter market; </TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left  >&#149;</TD>
    <TD align=left width="90%">in transactions otherwise than on these
      exchanges or services or in the over-the-counter market; or </TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left  >&#149;</TD>
    <TD align=left width="90%">through the writing of options, whether the
      options are listed on an options exchange or otherwise.
</TD></TR></TABLE>
<P align=center>8 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_14></A>
<P align=justify style="text-indent:5%">Each time that we use this prospectus to sell our securities,
we shall also provide a prospectus supplement. For each series of securities,
the applicable prospectus supplement will set forth the terms of the offering
including: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="5%"  >&nbsp;</TD>
    <TD align=left  >&#149;</TD>
    <TD align=left width="90%">the public offering price; </TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left  >&#149;&nbsp;</TD>
    <TD align=left width="90%">the name or names of any underwriters, dealers
      or agents; </TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left  >&#149;&nbsp;</TD>
    <TD align=left width="90%">the purchase price of the securities; </TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left  >&#149;&nbsp;</TD>
    <TD align=left width="90%">the proceeds from the sale of the securities to
      us; </TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left  >&#149;&nbsp;</TD>
    <TD align=left width="90%">any underwriting discounts, agency fees, or
      other compensation payable to underwriters or agents; </TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left  >&#149;&nbsp;</TD>
    <TD align=left width="90%">any discounts or concessions allowed or
      reallowed or repaid to dealers; and </TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left  >&#149;&nbsp;</TD>
    <TD align=left width="90%">the securities exchanges on which the
      securities will be listed, if any. </TD></TR></TABLE>
<P align=justify style="text-indent:5%">If we use underwriters in the sale of securities, the
securities will be acquired by the underwriters for their own account. The
underwriters may then resell the securities in one or more transactions at a
fixed public offering price or at varying prices determined at the time of sale
or thereafter. The securities may be either offered to the public through
underwriting syndicates represented by managing underwriters, or directly by
underwriters. The obligations of the underwriters to purchase the securities
will be subject to certain conditions. The underwriters will be obligated to
purchase all the securities offered if they purchase any securities. The public
offering price and any discounts or concessions allowed or re-allowed or paid to
dealers may be changed from time to time. </P>
<P align=justify style="text-indent:5%">If we use dealers in the sale of securities, we will sell
securities to such dealers as principals. The dealers may then resell the
securities to the public at varying prices to be determined by such dealers at
the time of resale. We may solicit offers to purchase the securities directly,
and we may sell the securities directly to institutional or other investors, who
may be deemed underwriters within the meaning of the Securities Act with respect
to any resales of those securities. The terms of these sales will be described
in the applicable prospectus supplement. If we use agents in the sale of
securities, unless otherwise indicated in the prospectus supplement, they will
use their reasonable best efforts to solicit purchases for the period of their
appointment. Unless otherwise indicated in a prospectus supplement, if we sell
directly, no underwriters, dealers or agents would be involved. We will not make
an offer of securities in any jurisdiction that does not permit such an offer.
</P>
<P align=justify style="text-indent:5%">We may grant underwriters who participate in the distribution
of securities an option to purchase additional securities to cover
overallotments, if any, in connection with the distribution. Any underwriter may
engage in overallotment, stabilizing transactions, short covering transactions
and penalty bids in accordance with SEC orders, rules and regulations and
applicable law. To the extent permitted by applicable law and SEC orders, rules
and regulations, an overallotment involves sales in excess of the offering size,
which create a short position. Stabilizing transactions permit bids to purchase
the underlying security so long as the stabilizing bids do not exceed a
specified maximum. To the extent permitted by applicable law and SEC orders,
rules and regulations, short covering transactions involve purchases of the
common stock in the open market after the distribution is completed to cover
short positions. Penalty bids permit the underwriters to reclaim a selling
concession from a dealer when the common stock originally sold by the dealer is
purchased in a covering transaction to cover short positions. Those activities
may cause the price of the common stock to be higher than it would otherwise be.
If commenced, the underwriters may discontinue any of the activities at any
time. </P>
<P align=justify style="text-indent:5%">Any underwriters who are qualified market makers on the NASDAQ
Stock Market may engage in passive market making transactions in the common
stock on the NASDAQ Stock Market in accordance with Rule 103 of Regulation M,
during the business day prior to the pricing of the offering, before the
commencement of offers or sales of the common stock. Passive market makers must
comply with applicable volume and price limitations and must be identified as
passive market makers. In general a passive market maker must display its bid at
a price not in excess of the highest independent bid for such security; if all
independent bids are lowered below the passive market maker&#146;s bid, however, the
passive market maker&#146;s bid must then be lowered when certain purchase limits are
exceeded. The anti-manipulation rules under the Exchange Act may apply to sales
of shares in the market. Furthermore, Regulation M may restrict the ability of
any person engaged in the distribution of the shares to engage in market-making
activities for the particular securities being distributed for a period of up to
five business days before the distribution. The restrictions may affect the
marketability of the shares and the ability of any person or entity to engage in
market-making activities for the shares. </P>
<P align=justify style="text-indent:5%">Underwriters, dealers and agents that participate in any
distribution of securities may be deemed to be underwriters as defined in the
Securities Act. Any discounts, commissions or profit they receive when they resell the securities may be treated as underwriting discounts
and commissions under the Securities Act. Only underwriters named in the
prospectus supplement are underwriters of the securities offered in the
prospectus supplement. We may have agreements with underwriters, dealers and
agents to indemnify them against certain civil liabilities, including certain
liabilities under the Securities Act, or to contribute with respect to payments
that they may be required to make. </P>
<P align=center>9 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_15></A>
<P align=justify style="text-indent:5%">We may authorize underwriters, dealers or agents to solicit
offers from certain institutions whereby the institution contractually agrees to
purchase the securities from us on a future date at a specific price. This type
of contract may be made only with institutions that we specifically approve.
Such institutions could include banks, insurance companies, pension funds,
investment companies and educational and charitable institutions. The
underwriters, dealers or agents will not be responsible for the validity or
performance of these contracts. </P>
<P align=justify style="text-indent:5%">Each series of securities will be a new issue of securities.
  Our Common Stock is quoted on the OTCQX. Unless otherwise specified in the
  applicable prospectus supplement, our securities (other than our Common Stock)
  will not be listed on any exchange. It has not presently been established
  whether the underwriters, if any, of the securities will make a market in the
  securities. If the underwriters make a market in the securities, such market
making may be discontinued at any time without notice. </P>
<P align=justify style="text-indent:5%">Agents, dealers and underwriters may be entitled to
indemnification by us against certain civil liabilities, including liabilities
under the Securities Act, or to contribution with respect to payments which the
agents, dealers or underwriters may be required to make in respect thereof.
Agents, dealers or underwriters may be customers of, engage in transactions
with, or perform services for us and our subsidiaries in the ordinary course of
business. </P>
<P align=justify><I>Secondary Offering </I></P>
<P align=justify style="text-indent:5%">The  common stock offered by this prospectus is being offered by the Selling  Security Holder. The common stock may be sold or distributed from time to time  by the selling stockholder directly to one or more purchasers or through brokers,  dealers, or underwriters who may act solely as agents at market prices  prevailing at the time of sale, at prices related to the prevailing market  prices, at negotiated prices, or at fixed prices, which may be changed. The  sale of the common stock offered by this prospectus could be affected in one or  more of the following methods:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="5%"  >&nbsp;</TD>
    <TD align=left >&#149; </TD>
    <TD align=left width="90%">ordinary brokers&rsquo; transactions; </TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&#149; </TD>
    <TD align=left width="90%">transactions involving cross or block trades; </TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&#149; </TD>
    <TD align=left width="90%">through brokers, dealers, or underwriters who  may act solely as agents; </TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&#149; </TD>
    <TD align=left width="90%">&ldquo;at the market&rdquo; into an existing market for the  common stock; </TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&#149; </TD>
    <TD align=left width="90%">in other ways not involving market makers or  established business markets, including direct sales to purchasers or sales  effected through agents; </TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&#149; </TD>
    <TD align=left width="90%">in privately negotiated transactions; or </TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left >&#149; </TD>
    <TD align=left width="90%">any combination of the foregoing.</TD></TR>
  </TABLE>
<P align=justify style="text-indent:5%">In  order to comply with the securities laws of certain states, if applicable, the  shares may be sold only through registered or licensed brokers or dealers. In  addition, in certain states, the shares may not be sold unless they have been  registered or qualified for sale in the state or an exemption from the state&rsquo;s  registration or qualification requirement is available and complied with.</p>
<P align=justify style="text-indent:5%">The  Selling Security Holder is an &ldquo;underwriter&rdquo; within the meaning of Section  2(a)(11) of the Securities Act.</p>
<P align=justify style="text-indent:5%">The  Selling Security Holder has informed us that it intends to use an unaffiliated  broker-dealer to effectuate all sales, if any, of the common stock that it may  purchase from us pursuant to the Purchase Agreement. Such sales will be made at  prices and at terms then prevailing or at prices related to the then current  market price. Each such unaffiliated broker-dealer will be an underwriter  within the meaning of Section 2(a)(11) of the Securities Act. The Selling  Security Holder has informed us that each such broker-dealer will receive  commissions from The Selling Security Holder that will not exceed customary  brokerage commissions. In compliance with the guidelines of the Financial  Industry Regulatory Authority, Inc., or FINRA, the maximum consideration or  discount to be received by any FINRA member or independent broker dealer may  not exceed 8% of the aggregate amount of the securities offered pursuant to  this prospectus.</p>
<P align=justify style="text-indent:5%">&nbsp;</P>
<P align=center>10 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_16></A>
<P align=justify style="text-indent:5%">Brokers,  dealers, underwriters or agents participating in the distribution of the shares  as agents may receive compensation in the form of commissions, discounts, or  concessions from the selling stockholder and/or purchasers of the common stock  for whom the broker-dealers may act as agent. The compensation paid to a  particular broker-dealer may be less than or in excess of customary  commissions. Neither we nor the Selling Security Holder can presently estimate  the amount of compensation that any agent will receive. We know of no existing  arrangements between the Selling Security Holder or any other stockholder,  broker, dealer, underwriter or agent relating to the sale or distribution of  the shares offered by this prospectus. At the time a particular offer of shares  is made, a prospectus supplement, if required, will be distributed that will  set forth the names of any agents, underwriters or dealers and any compensation  from the selling stockholder, and any other required information.</P>
<P align=justify style="text-indent:5%">We will pay the expenses incident to the registration,  offering, and sale of the shares to the Selling Security Holder. We have agreed  to indemnify&nbsp; and certain other persons  against certain liabilities in connection with the offering of shares of common  stock offered hereby, including liabilities arising under the Securities Act  or, if such indemnity is unavailable, to contribute amounts required to be paid  in respect of such liabilities.&nbsp; has  agreed to indemnify us against liabilities under the Securities Act that may  arise from certain written information furnished to us by&nbsp; specifically for use in this prospectus or,  if such indemnity is unavailable, to contribute amounts required to be paid in  respect of such liabilities.</P>
<P align=justify style="text-indent:5%">&nbsp;Lincoln Park has represented to us that at no  time prior to the Purchase Agreement has&nbsp;  or its agents, representatives or affiliates engaged in or effected, in  any manner whatsoever, directly or indirectly, any short sale (as such term is  defined in Rule 200 of Regulation SHO of the Exchange Act) of our common stock  or any hedging transaction, which establishes a net short position with respect  to our common stock.&nbsp; agreed that during  the term of the Purchase Agreement, it, its agents, representatives or  affiliates will not enter into or effect, directly or indirectly, any of the  foregoing transactions.</P>
<P align=justify style="text-indent:5%">We have advised the Selling Security Holder that it is  required to comply with Regulation M promulgated under the Exchange Act. With  certain exceptions, Regulation M precludes the selling stockholder, any affiliated  purchasers, and any broker-dealer or other person who participates in the  distribution from bidding for or purchasing, or attempting to induce any person  to bid for or purchase any security which is the subject of the distribution  until the entire distribution is complete. Regulation M also prohibits any bids  or purchases made in order to stabilize the price of a security in connection  with the distribution of that security. All of the foregoing may affect the  marketability of the securities offered by this prospectus.</P>
<P align=justify style="text-indent:5%">Our common stock is quoted on the OTCQX under the symbol
&#147;AVXLD.&#148;</P>
<P align=justify style="text-indent:5%">When we refer to &#147;Selling Security Holder&#148; in this prospectus,
we mean the entity listed in the table below, and the pledgees, donees,
permitted transferees, assignees, successors, and others who later come to hold
any of the Selling Security Holder&#146;s interests in shares of our common stock
other than through a public sale.</P>
<P align=center>11 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_17></A>
<P align=center><B>SELLING SECURITY HOLDER </B></P>
<P align=justify style="text-indent:5%">An aggregate of $50,000,000 of Common Stock and up to 269,397
shares of Common Stock may be offered for sale and sold from time to time
pursuant to this prospectus by the Selling Security Holder and its respective
transferees, distributees, pledgees, donees, assignees or other successors.
Except as may be set forth in any accompanying prospectus supplement, we will
pay all of the expenses in connection with the registration and the sale of the
shares, other than selling commissions and the fees and expenses of counsel and
other advisors to the Selling Security Holder. We will not receive any proceeds
from the sale of shares by the Selling Security Holder. Information concerning
the Selling Security Holder may change from time to time, and any changed
information will be set forth if and when required in the applicable prospectus
supplements.</P>
<P align=justify style="text-indent:5%">On October 21, 2015, the Company entered into the Purchase
Agreement with the Selling Security Holder. In connection with the Financing,
the Company also entered into the RRA whereby the Company agreed to file a
registration statement with the SEC covering the shares of the Company&#146;s Common
Stock that may be issued to the Selling Security Holder under the Purchase
Agreement. The shares being registered hereunder are being registered pursuant
to the terms of the RRA. </P>
<P align=justify style="text-indent:5%">After the SEC has declared effective this registration
statement related to the Financing, the Company has the right, in its sole
discretion over a 36-month period, to sell to the Selling Security Holder up an
aggregate commitment of $50,000,000 of shares of Common Stock. The Company
controls the timing and amount of any future sales, if any, of shares of common
stock to the Selling Security Holder.</P>
<P align=justify style="text-indent:5%">The Purchase Agreement contains customary representations,
warranties, covenants, closing conditions and indemnification and termination
provisions by, among and for the benefit of the parties. The Selling Security
Holder has covenanted not to cause or engage in any manner whatsoever, any
direct or indirect short selling or hedging of the Company&#146;s Common Stock.</P>
<P align=justify style="text-indent:5%">In consideration for entering into the Purchase  Agreement, the Company issued to the Selling Security Holder, 179,598 shares of  Common Stock as a commitment fee and shall issue up to 89,799 shares pro rata,  when and if, the Selling Security Holder purchases at the Company&rsquo;s discretion  the $50,000,000 aggregate commitment. For example, if we elect, at our sole  discretion, to require the Selling Security Holder to purchase $100,000 of our  stock then we would issue 180 shares of the pro rata commitment fee which is  the product of $100,000 (the amount we have elected to sell) divided by  $50,000,000 (the amount we can sell the Selling Security Holder under the  Purchase Agreement multiplied by 89,799 (the total number of pro rata  commitment shares).&nbsp; The pro rata commitment  shares will only be issued pursuant to this formula as and when we elect at our  discretion to sell stock to the Selling Security Holder.&nbsp; The Selling Security Holder may not assign or  transfer its rights and obligations under the Purchase Agreement. The Purchase  Agreement may be terminated by the Company at any time at its discretion  without any cost to the Company.</P>
<P align=justify style="text-indent:5%">Pursuant to the Registration Rights Agreement, dated as of
October 21, 2015, among the Selling Security Holder and the Company, the Selling
Security Holder has the right to request that the Company include their shares
on the registration statement of which this prospectus forms a part under the
Securities Act. Under the Registration Rights Agreement, the Selling Security
Holder has registration rights with respect to the shares of Common Stock set
forth in the table below.</P>
<P align=justify style="text-indent:5%">As of October 19, 2015, the Selling Security Holder
beneficially owned, in the aggregate, 70,000 shares of Common Stock, or 0.21% of
our outstanding Common Stock. We cannot provide an estimate as to the number of
shares of common stock that will be held by the Selling Security Holder upon
consummation of any offering or offerings covered by this prospectus because the
Selling Security Holder may offer some, all or none of their shares of Common
Stock in any such offering or offerings. The Selling Security Holder does not
and has not within the past three years had, any position, office or material
relationship with us or any of our predecessors or affiliates.<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%"><B>Percentage of </B></TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%"><B>Percentage of </B></TD>
    <TD vAlign=bottom align=left width="3%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%"><B>Outstanding </B></TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%"><B>Outstanding </B></TD>
    <TD vAlign=bottom align=left width="3%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%"><B>Shares </B></TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%"><B>Shares </B></TD>
    <TD vAlign=bottom align=left width="3%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%"><B>Shares Beneficially </B></TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%"><B>Beneficially </B></TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%"><B>Beneficially </B></TD>
    <TD vAlign=bottom align=left width="3%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%"><B>Owned Before this </B></TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%"><B>Owned Before </B></TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%"><B>No. of Shares to be </B></TD>
    <TD vAlign=bottom noWrap align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="11%"><B>Owned After </B></TD>
    <TD vAlign=bottom align=left width="3%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom
      align=left>&nbsp;<B>Selling Shareholder </B></TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="11%"><B>Offering </B></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="11%"><B>this Offering </B></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="11%"><B>Re</B><B>gistered in this Offering </B></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="3%">&nbsp;</TD>
    <TD vAlign=bottom noWrap align=center width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom noWrap
    align=center width="11%"><B>this Offering </B></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="3%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left vAlign=bottom bgcolor="#E6EFFF">Lincoln Park Capital </TD>
    <TD width="1%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="11%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="3%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="1%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="11%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="3%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="1%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="11%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="3%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="1%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="11%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="3%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left vAlign=bottom bgcolor="#E6EFFF">Fund, LLC (1) </TD>
    <TD width="1%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="11%" align=right vAlign=bottom bgcolor="#E6EFFF">249,598</TD>
    <TD width="3%" align=left vAlign=bottom bgcolor="#E6EFFF">(2) </TD>
    <TD width="1%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="11%" align=right vAlign=bottom bgcolor="#E6EFFF">1.00% </TD>
    <TD width="3%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="1%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="11%" align=right vAlign=bottom bgcolor="#E6EFFF">6,754,609</TD>
    <TD width="3%" align=left vAlign=bottom bgcolor="#E6EFFF">(4) </TD>
    <TD width="1%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
    <TD width="11%" align=right vAlign=bottom bgcolor="#E6EFFF">* </TD>
    <TD width="3%" align=left vAlign=bottom bgcolor="#E6EFFF">&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=bottom>&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="11%">&nbsp;</TD>
    <TD vAlign=bottom width="3%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="11%">&nbsp;</TD>
    <TD vAlign=bottom width="3%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="11%">&nbsp;</TD>
    <TD vAlign=bottom width="3%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="11%">&nbsp;</TD>
    <TD vAlign=bottom width="3%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    colSpan=3>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp;<B>* Less than 1% </B></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="3%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="11%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="3%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="11%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="3%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="11%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="3%">&nbsp;</TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD vAlign=top width="5%">(1) </TD>
    <TD><P align=justify>Josh Scheinfeld and Jonathan Cope, the Managing Members
      of Lincoln Park Capital, LLC, are deemed to be beneficial owners of all of
      the shares of common stock owned by Lincoln Park Capital Fund, LLC.
      Messrs. Cope and Scheinfeld have shared voting and investment power over
      the shares being offered under the prospectus filed with the SEC in
      connection with the transactions contemplated under the Purchase
      Agreement. Lincoln Park Capital, LLC is not a licensed broker dealer or an
      affiliate of a licensed broker dealer.</P></TD>
  </TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top width="5%">(2) </TD>
    <TD><P align=justify>Represents 70,000 shares of Common Stock held by the
      Selling Security Holder prior to this offering, and 179,598 shares of our
      Common Stock issued to the Selling Security Holder on or about October 21,
      2015 as a fee for its commitment to purchase additional shares of our
      common stock under the Purchase Agreement, all of which shares are covered
      by the registration statement that includes this
      prospectus.</P></TD>
  </TR>
</TABLE>
<p align="center">12</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=-->
<A name=page_20a></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD vAlign=top width="5%">(3) </TD>
    <TD><P align=justify>Based on 33,789,938 outstanding shares of our common
      stock as of October 21, 2015, with the above mentioned commitment shares
      deemed issued as of that date.</P></TD>
  </TR>
  <TR>
    <TD vAlign=top>(4)</TD>
    <TD vAlign=top><div align="justify">Although the Purchase Agreement provides that we may sell up to $50,000,000 of our Common Stock to      Lincoln Park, we have initially reserved approximately 6,754,609 shares for sale to Lincoln Park under the Purchase Agreement and RRA. The amount of shares of Common Stock we may sell to Lincoln Park is subject to cap on issuable shares as described in the Purchase Agreement.</div></TD>
  </TR>
</TABLE>
<P align=justify><B>The Lincoln Park Transaction </B></P>
<P align=justify><U>General</U> </P>
<P align=justify style="text-indent:5%">On October 21, 2015, we entered
  into the Purchase Agreement and the Registration Rights Agreement with Lincoln
  Park. Pursuant to the terms of the Purchase Agreement, Lincoln Park has agreed
  to purchase from us up to $50,000,000 of our Common Stock (subject to certain
  limitations) from time to time over a 36-month period starting in October 2015.
  Pursuant to the terms of the Registration Rights Agreement, we have filed with
  the SEC the registration statement that includes this prospectus to register for
  resale under the Securities Act the shares that have been or may be issued to
  Lincoln Park under the Purchase Agreement.</P>
<P align=justify style="text-indent:5%">After  the SEC has declared effective the registration statement, we may, from time to  time and at our sole discretion but no more frequently than every other  business day, direct Lincoln Park to purchase 50,000 shares of our Common Stock  on any such business day, which amounts may be increased under certain  circumstances, provided that in no event shall Lincoln Park purchase more than  $2,000,000 worth of our Common Stock on any single business day, plus an  additional &ldquo;accelerated amount&rdquo; under certain circumstances, at a purchase  price per share based on the market price of our common stock immediately  preceding the time of sale as computed under the Purchase Agreement without any  fixed discount. The amount of shares of our Common Stock that we direct Lincoln  Park to purchase depends on the closing price of our Common Stock.</P>
<P align=justify><U>Purchase of Shares Under the Purchase Agreement</U> </P>
<P align=justify style="text-indent:5%">Under  the Purchase Agreement, on any business day selected by us, we may direct  Lincoln Park to purchase 50,000 shares of our Common Stock on any such business  day. On any day that the closing sale price of our common stock is not below  $7.00 the purchase amount may be increased, at our sole discretion, to up  to75,000 shares of our common stock per purchase; on any day that the closing  sale price of our common stock is not below $9.00 the purchase amount may be  increased, at our sole discretion, to up to 100,000 shares of our common stock  per purchase and on any day that the closing sale price of our common stock is  not below $11.00 the purchase amount may be increased, at our sole discretion,  to up to 125,000 shares of our common stock per purchase and on any day that the  closing sale price of our common stock is not below $13.00 the purchase amount  may be increased, at our sole discretion, to up to 150,000 shares of our common  stock per purchase. Such purchases are hereinafter referred to as &ldquo;Regular  Purchases&rdquo;. In no event shall Lincoln Park purchase more than $2,000,000 worth  of our common stock pursuant to a Regular Purchase on any single business day.  The purchase price per share for each such Regular Purchase will be equal to  the lower of:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>the lowest sale price for our common stock on the purchase date of such
    shares; or
  <LI>the arithmetic average of the three lowest closing sale prices for our
    common stock during the 10 consecutive business days ending on the business
    day immediately preceding the purchase date of such shares. </LI>
</UL>
<P align=justify>In addition to Regular Purchases described above, we may also
  direct Lincoln Park, on any business day on which we have properly submitted a
  Regular Purchase notice, to purchase an additional amount of our Common Stock,
  which we refer to as an Accelerated Purchase, not to exceed the lesser of: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>30% of the aggregate shares of our common stock traded during normal
    trading hours on the purchase date; and
  <LI>200% of the number of purchase shares purchased pursuant to the
    corresponding Regular Purchase. </LI>
</UL>
<P align=justify>The purchase price per share for each such Accelerated Purchase
  will be equal to the lower of: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>96% of the volume weighted average price during (i) the entire trading day
    on the purchase date, if the volume of shares of our common stock traded on
    the purchase date has not exceeded a volume maximum calculated in accordance
    with the Purchase Agreement, or (ii) the portion of the trading day of the
    purchase date (calculated starting at the beginning of normal trading hours)
    until such time at which the volume of shares of our common stock traded has
    exceeded such volume maximum; or
  <LI>the closing sale price of our common stock on the purchase date. </LI>
</UL>
<P align=justify>In the case of both Regular Purchases and Accelerated
  Purchases, the purchase price per share will be equitably adjusted for any
  reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring during the
  business days used to compute the purchase price. </P>
<P align=center>13</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=-->
<A name=page_21a></A>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other than as set forth above,
  there are no trading volume requirements or restrictions under the Purchase
  Agreement, and we will control the timing and amount of any sales of our common
  stock to Lincoln Park. </P>
<P align=justify><U>Events of Default</U> </P>
<P align=justify>Events of default under the Purchase Agreement include the
  following: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
    <P>the effectiveness of the registration statement of which this prospectus
      forms a part lapses for any reason (including, without limitation, the
      issuance of a stop order), or any required prospectus supplement and
      accompanying prospectus are unavailable for the resale by Lincoln Park of our
      common stock offered hereby, and such lapse or unavailability continues for a
      period of 10 consecutive business days or for more than an aggregate of 30
      business days in any 365-day period; </P>
  <LI>
    <P>suspension by our principal market of our common stock from trading for a
      period of three consecutive business days; </P>
  <LI>
    <P>the delisting of the Common Stock from the OTCQB operated by the OTC
      Markets Group, Inc., provided, however, that the Common Stock is not
      immediately thereafter trading on the New York Stock Exchange, The NASDAQ
      Capital Market, The NASDAQ Global Market, The NASDAQ Global Select Market, the
      NYSE MKT, the NYSE Arca, the OTC Bulletin Board or the OTCQX operated by the
      OTC Markets Group, Inc. (or nationally recognized successor to any of the
      foregoing). If at any time after the Commencement Date, the Exchange Cap is
      reached unless and until stockholder approval is obtained pursuant to Section
      2(e) hereof. The Exchange Cap shall be deemed to be reached at such time if,
      upon submission of a Regular Purchase Notice or Accelerated Purchase Notice
      under this Agreement, the issuance of such shares of Common Stock would exceed
      that number of shares of Common Stock which the Company may issue under this
      Agreement without breaching the Company&#146;s obligations under the rules or
      regulations of the Principal Market; </P>
  <LI>
    <P>the transfer agent&#146;s failure for three business days to issue to Lincoln
      Park shares of our Common Stock which Lincoln Park is entitled to receive
      under the Purchase Agreement; </P>
  <LI>
    <P>any breach of the representations or warranties or covenants contained in
      the Purchase Agreement or any related agreement which has or which could have
      a material adverse effect on us subject to a cure period of five business
      days; </P>
  <LI>
    <P>any voluntary or involuntary participation or threatened participation in
      insolvency or bankruptcy proceedings by or against us; and </P>
  <LI>
    <P>if at any time we are not eligible to transfer our common stock
      electronically or a material adverse change in our business, financial
      condition, operations or prospects has occurred. </P>
  </LI>
</UL>
<P align=justify>Lincoln Park does not have the right to terminate the Purchase
  Agreement upon any of the events of default set forth above. During an event of
  default, all of which are outside of Lincoln Park&#146;s control, shares of our
  common stock cannot be sold by us or purchased by Lincoln Park under the
  Purchase Agreement. </P>
<P align=justify><U>Our Termination Rights</U> </P>
<P align=justify style="text-indent:5%">We have the unconditional right,
  at any time, for any reason and without any payment or liability to us, to give
  notice to Lincoln Park to terminate the Purchase Agreement. In the event of
  bankruptcy proceedings by or against us, the Purchase Agreement will
  automatically terminate without action of any party. </P>
<P align=justify><U>No Short-Selling or Hedging by Lincoln Park</U> </P>
<P align=justify style="text-indent:5%">Lincoln Park has agreed that
  neither it nor any of its affiliates shall engage in any direct or indirect
  short-selling or hedging of our common stock during any time prior to the
  termination of the Purchase Agreement. </P>
<P align=center>14</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=-->
<A name=page_22></A>
<P align=justify><B>Effect of Performance of the Purchase Agreement on Our
  Stockholders </B></P>
<P align=justify style="text-indent:5%">All the shares of our
  Common Stock registered in this offering which may be sold by us to Lincoln Park
  under the Purchase Agreement are expected to be freely tradable. It is
  anticipated that shares registered in this offering will be sold over a period
  of up to 36 months commencing on the date that the registration statement
  including this prospectus becomes effective. The sale by Lincoln Park of a
  significant amount of shares registered in this offering at any given time could
  cause the market price of our common stock to decline and to be highly volatile.
  Lincoln Park may ultimately purchase all, some or none of the shares of common
  stock registered in this offering that Lincoln Park has not previously
  purchased. Lincoln Park may sell all, some or none of the shares it has
  purchased or will purchase under the Purchase Agreement. Therefore, sales to
  Lincoln Park by us under the Purchase Agreement may result in substantial
  dilution to the interests of other holders of our common stock. In addition, if
  we sell a substantial number of shares to Lincoln Park under the Purchase
  Agreement, or if investors expect that we will do so, the actual sales of shares
  or the mere existence of our arrangement with Lincoln Park may make it more
  difficult for us to sell equity or equity-related securities in the future at a
  time and at a price that we might otherwise wish to effect such sales. However,
  we have the right to control the timing and amount of any sales of our shares to
  Lincoln Park and the Purchase Agreement may be terminated by us at any time at
  our discretion without any cost to us. </P>
<P align=justify style="text-indent:5%">Pursuant to the terms of the
  Purchase Agreement, we have the right, but not the obligation, to direct Lincoln
  Park to purchase up to $50,000,000 of our common stock, exclusive of the 179,958
  shares issued to Lincoln Park as a commitment fee. Depending on the price per
  share at which we sell our common stock to Lincoln Park, we may be authorized to
  issue and sell to Lincoln Park under the Purchase Agreement more shares of our
  common stock than are offered under this prospectus. If we choose to do so, we
  must first register for resale under the Securities Act any such additional
  shares, which could cause additional substantial dilution to our stockholders.
  The number of shares ultimately offered for resale by Lincoln Park under this
  prospectus is dependent upon the number of shares we direct Lincoln Park to
  purchase under the Purchase Agreement. </P>
<P align=justify style="text-indent:5%">The following table sets forth
  the amount of gross proceeds we would receive from Lincoln Park from our sale of
  shares to Lincoln Park under the Purchase Agreement registered in this offering
  at varying purchase prices: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=left valign="bottom" nowrap  >&nbsp;</TD>
    <TD width="22%" align=left valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap  >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" nowrap><B>Percentage of</B> </TD>
    <TD width="2%" align=center valign="bottom" nowrap  >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" nowrap><B>Proceeds from the Sale</B> </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=left valign="bottom" nowrap  >&nbsp;</TD>
    <TD width="22%" align=left valign="bottom" nowrap>&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" nowrap  >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" nowrap><B>Outstanding Shares</B> </TD>
    <TD width="2%" align=center valign="bottom" nowrap  >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" nowrap><B>of Shares to Lincoln</B> </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center valign="bottom" nowrap><B>Assumed Average</B> </TD>
    <TD width="2%" align=center valign="bottom" nowrap  >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" nowrap><B>Number of Registered</B> </TD>
    <TD width="2%" align=center valign="bottom" nowrap  >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" nowrap><B>After Giving Effect to</B> </TD>
    <TD width="2%" align=center valign="bottom" nowrap  >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" nowrap><B>Park Under the</B> </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center valign="bottom" nowrap><B>Purchase Price</B> </TD>
    <TD width="2%" align=center valign="bottom" nowrap  >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" nowrap><B>Shares to be Issued</B> </TD>
    <TD width="2%" align=center valign="bottom" nowrap  >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" nowrap><B>the Issuance to</B> </TD>
    <TD width="2%" align=center valign="bottom" nowrap  >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" nowrap><B>$50,000,000</B> </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"><B>Per Share</B> </TD>
    <TD width="2%" align=center valign="bottom" nowrap  >&nbsp;</TD>
    <TD
      width="22%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"><B>if Full Purchase(1)(2)</B> </TD>
    <TD width="2%" align=center valign="bottom" nowrap  >&nbsp;</TD>
    <TD
      width="22%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"><B>Lincoln Park (3)</B> </TD>
    <TD width="2%" align=center valign="bottom" nowrap  >&nbsp;</TD>
    <TD
      width="22%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid"><B>Purchase Agreement</B> </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center valign="bottom" bgColor=#e6efff>$1.00<SUP>(4)</SUP> </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>6,485,212 </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>16.10% </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>$6,485,212 </TD>
  </TR>
  <TR>
    <TD align=center valign="bottom" >&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=center valign="bottom" bgColor=#e6efff>$5.00 </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>6,485,212 </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>16.10% </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>$32,426,060 </TD>
  </TR>
  <TR>
    <TD align=center valign="bottom" >&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=center valign="bottom" bgColor=#e6efff>$7.87<SUP>(5)</SUP> </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>6,353,240 </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>15.83% </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>$49,999,999 </TD>
  </TR>
  <TR>
    <TD align=center valign="bottom" >&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=center valign="bottom" bgColor=#e6efff>$10.00 </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>5,000,000 </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>12.89% </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>$50,000,000 </TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp;</TD>
    <TD width="2%" valign="bottom"  >&nbsp;</TD>
    <TD width="22%" valign="bottom">&nbsp;</TD>
    <TD width="2%" valign="bottom"  >&nbsp;</TD>
    <TD width="22%" valign="bottom">&nbsp;</TD>
    <TD width="2%" valign="bottom"  >&nbsp;</TD>
    <TD width="22%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=center valign="bottom" bgColor=#e6efff>$20.00 </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>2,500,000 </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>6.89% </TD>
    <TD width="2%" align=center valign="bottom"  bgColor=#e6efff
    >&nbsp;</TD>
    <TD width="22%" align=center valign="bottom" bgColor=#e6efff>$50,000,000 </TD>
  </TR>
</TABLE>
____________________<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD vAlign=top width="5%">(1) </TD>
    <TD><P align=justify>Although the Purchase Agreement provides that we  may sell up to $50,000,000 of our common stock to Lincoln Park, we are  initially reserving 6,754,609 shares (inclusive of the 269,397 shares issued to  Lincoln Park as a commitment fee), which may or may not cover all the shares we  ultimately sell to Lincoln Park under the Purchase Agreement, depending on the  purchase price per share. As a result, we have included in this column only  those shares that we have initially reserved.</P></TD>
  </TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top width="5%">(2) </TD>
    <TD><P align=justify>The number of registered shares to be issued excludes the
      269,397 commitment shares because no proceeds will be attributable to such
      commitment shares.</P></TD>
  </TR>
</TABLE>
<p align="center">15</p>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=-->
<A name="page_23a"></A> <BR>
<TABLE BCLLIST style="font-size:10pt;border-color:black;border-collapse:collapse;" cellpadding="0" cellspacing="0" width="100%" border="0">
  <TR>
    <TD width=5% valign=top> (3) </TD>
    <TD><P align="justify">The denominator is based on 33,789,938 shares outstanding as of October 21, 2015, adjusted to include the 269,397 shares issued to Lincoln Park as commitment shares in connection with this offering and the number of shares set
      forth in the adjacent column which we would have sold to Lincoln Park at the applicable assumed average purchase price per share. The numerator does not include the 269,397 shares issued to Lincoln Park as commitment shares in connection with this
      offering, and is based on the number of shares registered in this offering to be issued under the Purchase Agreement at the applicable assumed purchase price per share set forth in the adjacent column. The number of shares in such column does not
      include shares that may be issued to Lincoln Park under the Purchase Agreement which are not registered in this offering.</P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>

  <TR>
    <TD width=5% valign=top> (4) </TD>
    <TD><P align="justify">The closing price of our Common Stock on October 22, 2015.</P></TD>
  </TR>
</TABLE>
<!--$$/page=-->
<P align=center><B>DESCRIPTION OF OUR CAPITAL STOCK </B></P>
<P align=left><B>Common Stock </B></P>
<P align=justify style="text-indent:5%">We are authorized to issue 100,000,000 shares of common stock
with a par value of $0.001. As at October 21, 2015 we had 33,789,938 common
shares outstanding. Upon liquidation, dissolution or winding up of the
corporation, the holders of common stock are entitled to share ratably in all
net assets available for distribution to stockholders after payment to
creditors. The common stock is not convertible or redeemable and has no
preemptive, subscription or conversion rights. There are no conversion,
redemption, sinking fund or similar provisions regarding the common stock. Each
outstanding share of common stock is entitled to one vote on all matters
submitted to a vote of stockholders. There are no cumulative voting rights. </P>
<P align=justify style="text-indent:5%">Each stockholder is entitled to receive the dividends as may be
declared by our board of directors out of funds legally available for dividends
and, in the event of liquidation, to share pro rata in any distribution of our
assets after payment of liabilities. Our board of directors is not obligated to
declare a dividend. Any future dividends will be subject to the discretion of
our board of directors and will depend upon, among other things, future
earnings, the operating and financial condition of our Company, its capital
requirements, general business conditions and other pertinent factors. It is not
anticipated that dividends will be paid in the foreseeable future. </P>
<P align=justify style="text-indent:5%">On October 7, 2015, the Company effected a reverse stock split
at a ration of 1 for 4, whereby every 4 shares of common stock became 1 share of
common stock. The authorized shares of common stock of the Company were
therefore proportionally reduced from 400,000,000 to 100,000,000. </P>
<P align=justify style="text-indent:5%">Our common stock is quoted on the OTC Markets - OTCQX under the
trading symbol &#147;AVXLD&#148;. On October 21, 2015, the last reported sale price of our
common stock was $8.94 per share. </P>
<P align=justify><B>Nevada Anti-Takeover Law and Charter and Bylaws
Provisions</B> </P>
<P align=justify style="text-indent:5%">Nevada Revised Statutes sections 78.378 to 78.3793 provide
state regulation over the acquisition of a controlling interest in certain
Nevada corporations unless the articles of incorporation or bylaws of the
corporation provide that the provisions of these sections do not apply. The
statute creates a number of restrictions on the ability of a person or entity to
acquire control of a Nevada company by setting down certain rules of conduct and
voting restrictions in any acquisition attempt, among other things. The statute
is limited to corporations that are organized in the state of Nevada and that
have 200 or more shareholders, at least 100 of whom are shareholders of record
and residents of the State of Nevada; and do business in the State of Nevada
directly or through an affiliated corporation. Because of these conditions, the
statute does not apply to our Company. </P>
<P align=justify style="text-indent:5%">There are no provisions in our articles of incorporation or our
bylaws that would delay, defer or prevent a change in control of our
Company.</P>
<P align=center><B>LEGAL MATTERS </B></P>
<P align=justify style="text-indent:5%">The validity of the securities offered by this prospectus has
been passed upon for us by Snell &amp; Wilmer, L.L.P., Reno, Nevada. If legal
matters in connection with offerings made pursuant to this prospectus are passed
upon by counsel for the underwriters, dealers or agents, if any, such counsel
will be named in the prospectus supplement relating to such offering. </P>
<P align=center><B>EXPERTS</B></P>
<P align=justify style="text-indent:5%">The financial statements as of September 30, 2014 and 2013 and
for each of the two years in the period ended September 30, 2014 incorporated by
reference in this prospectus have been so incorporated in reliance on the report
of BDO USA, LLP, an independent registered public accounting firm, incorporated
herein by reference, given on the authority of said firm as experts in auditing
and accounting.</P>
<P align=center>16</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_19></A>
<P align=center><B>DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION</B></P>
<P align=justify style="text-indent:5%">Insofar as indemnification for liabilities arising under the
Securities Act, as amended, may be permitted to directors, officers, and
controlling persons of the registrant pursuant to the Company&#146;s constituent
documents, or otherwise, the registrant has been advised that in the opinion of
the SEC such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer, or controlling person in the successful defense
of any action, suit, or proceeding) is asserted by such director, officer, or
controlling person connected with the securities being registered, we will,
unless in the opinion of our counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue.
</P>
<P align=center>17</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_20></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-TOP: #000000 2px solid" align=center><B>ANAVEX LIFE
      SCIENCES CORP.</B> </TD></TR>
  <TR>
    <TD align=center>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=center><B>$100,000,000 </B>of S<B>hares of Common Stock</B> </TD>
  </TR>
  <TR>
    <TD align=center>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center><B>$50,000,000 </B>of S<B>hares of Common Stock and 269,397
      Shares of Common Stock</B> </TD>
  </TR>
  <TR>
    <TD align=center>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 2px solid"
      align=center><B>PROSPECTUS</B> </TD></TR></TABLE>
<P align=center>18 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_21></A>
<P align=center><B>PART II </B></P>
<P align=center><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B> </P>
<P align=justify><B>Item 14. Other Expenses of Issuance and
      Distribution.</B></P>
<P align=justify style="text-indent:5%">The following table sets forth the various expenses (other than
underwriting discounts and commissions) in connection with the issuance and
distribution of the securities registered hereby. The Company will bear all of
these expenses. All amounts are estimated except for the SEC registration
fee:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD vAlign=bottom align=left bgColor=#e6efff>SEC registration fee </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="27%" bgColor=#e6efff>&nbsp;15,105 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>Legal fees and expenses </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="27%">3,500</TD>
  <TD vAlign=bottom align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left bgColor=#e6efff>Accounting fees and expenses
    </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="27%" bgColor=#e6efff>10,000 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>Miscellaneous fees and expenses </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="27%">- </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="27%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom align=left>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp;Total expenses </TD>
    <TD vAlign=bottom align=left width="1%">$</TD>
    <TD vAlign=bottom align=right width="27%">28,605</TD>
  <TD vAlign=bottom align=left width="2%">&nbsp;</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-TOP: #000000 1px solid" align=left>* Estimated expenses
      are not presently known. </TD></TR></TABLE>
      <P align=justify><B>Item 15. Indemnification of Directors and
      Officers.</B></P>
<P align=justify style="text-indent:5%">Under the Nevada Revised Statutes, director immunity from
liability to a company or its shareholders for monetary liabilities applies
automatically unless it is specifically limited by a company&#146;s Articles of
Incorporation. </P>
<P align=justify style="text-indent:5%">Our Bylaws provide we have the power to indemnify, to the
greatest allowable extent permitted under the Nevada Revised Statutes, directors
or officers of our Company for any duties or obligations arising out of any acts
or conduct of the officer or director performed for or on behalf of our Company.
We will reimburse each such person for all legal and other expenses reasonably
incurred by him in connection with any such claim or liability, including power
to defend such persons from all suits or claims as provided for under the
provisions of the Nevada Revised Statutes. </P>
<P align=justify style="text-indent:5%">Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons
of our Company under Nevada law or otherwise, our Company has been advised that
the opinion of the Securities and Exchange Commission is that such
indemnification is against public policy as expressed in the Securities Act of
1933 and is, therefore, unenforceable. </P>
<P align=justify style="text-indent:5%">At present, there is no pending litigation or proceeding
involving any of our directors, officers or employees in which indemnification
is sought, nor are we aware of any threatened litigation that may result in
claims for indemnification. </P>
<P align=justify><B>Item 16. Exhibits.</B></P>
<P align=justify style="text-indent:5%">The exhibits to this registration statement are listed on the
exhibit index, which appears elsewhere herein and is incorporated herein by
reference.</P>
<P align=justify><B>Item 17. Undertakings.</B></P>
<P style="MARGIN-LEFT: 5%" align=justify>The undersigned registrant hereby
undertakes: </P>
<P align=justify style="margin-left:5%;text-indent:5%;">(a)(1) To file, during any period in
which offers or sales are being made, a post-effective amendment to this
registration statement: </P>
<P align=justify style="margin-left:10%;text-indent:5%;">(i) to include any prospectus required
by Section 10(a)(3) of the Securities Act of 1933, as amended; </P>
<P align=justify style="margin-left:10%;text-indent:5%;">(ii) to reflect in the prospectus any
facts or events arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which, individually or in
the aggregate, represent a fundamental change in the information set forth in
the registration statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the SEC
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price
represent no more than 20 percent change in the maximum aggregate offering price
set forth in the &#147;Calculation of Registration Fee&#148; table in the effective
registration statement; and </P>
<P align=center>II-1 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_22></A>
<P align=justify style="margin-left:10%;text-indent:5%;">(iii) to include any material information with respect to the
plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement; </P>
<P align=justify style="margin-left:10%;text-indent:5%;"><I>Provided, however,</I> that paragraphs (1)(i), (1)(ii) and
  (1)(iii) above do not apply if the registration statement is on Form S-3 or Form
  F-3 and the information required to be included in a post-effective amendment by
  those paragraphs is contained in reports filed with or furnished to the SEC by
  the registrant pursuant to Section 13 or 15(d) of the Securities Exchange Act of
  1934 that are incorporated by reference in the registration statement, or is
  contained in a form of prospectus filed pursuant to Rule 424(b) that is part of
the registration statement. </P>
<P align=justify style="margin-left:5%;text-indent:5%;">(2) That, for the purpose of determining any liability under
the Securities Act of 1933, as amended, each such post-effective amendment shall
be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof. </P>
<P align=justify style="margin-left:5%;text-indent:5%;">(3) To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at the
termination of the offering. </P>
<P align=justify style="margin-left:5%;text-indent:5%;">(4) That, for the purpose of determining liability under the
Securities Act of 1933, as amended, to any purchaser: </P>
<P align=justify style="margin-left:10%;text-indent:5%;">(i) Each prospectus filed by the registrant pursuant to Rule
424(b)(3) shall be deemed to be part of the registration statement as of the
date the filed prospectus was deemed part of and included in the registration
statement; and </P>
<P align=justify style="margin-left:10%;text-indent:5%;">(ii) Each prospectus required to be filed pursuant to Rule
424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on
Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or
(x) for the purpose of providing the information required by Section 10(a) of
the Securities Act of 1933 shall be deemed to be part of and included in the
registration statement as of the earlier of the date such form of prospectus is
first used after effectiveness or the date of the first contract of sale of
securities in the offering described in the prospectus. As provided in Rule
430B, for liability purposes of the issuer and any person that is at that date
an underwriter, such date shall be deemed to be a new effective date of the
registration statement relating to the securities in the registration statement
to which the prospectus relates, and the offering of such securities at that
time shall be deemed to be the initial <I>bona fide</I> offering thereof.
<I>Provided, however,</I> that no statement made in a registration statement or
prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will, as to a purchaser
with a time of contract of sale prior to such effective date, supersede or
modify any statement that was made in the registration statement or prospectus
that was part of the registration statement or made in any such document
immediately prior to such effective date. </P>
<P align=justify style="margin-left:5%;text-indent:5%;">(5) That, for the purpose of determining liability of the
registrant under the Securities Act of 1933, as amended, to any purchaser in the
initial distribution of the securities, the undersigned registrant undertakes
that in a primary offering of securities of the undersigned registrant pursuant
to this registration statement, regardless of the underwriting method used to
sell the securities to the purchaser, if the securities are offered or sold to
such purchaser by means of any of the following communications, the undersigned
registrant will be a seller to the purchaser and will be considered to offer or
sell such securities to such purchaser: </P>
<P align=justify style="margin-left:10%;text-indent:5%;">(i) Any preliminary prospectus or prospectus of the undersigned
registrant relating to the offering required to be filed pursuant to Rule 424;
</P>
<P align=justify style="margin-left:10%;text-indent:5%;">(ii) Any free writing prospectus relating to the offering
prepared by or on behalf of the undersigned registrant or used or referred to by
the undersigned registrant; </P>
<P align=justify style="margin-left:10%;text-indent:5%;">(iii) The portion of any other free writing prospectus relating
to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and
</P>
<P align=center>II-2 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_23></A>
<P align=justify style="margin-left:10%;text-indent:5%;">(iv) Any other communication that is an offer in the offering
made by the undersigned registrant to the purchaser. </P>
<P align=justify style="margin-left:5%;text-indent:5%;">(b) That, for purposes of determining any liability under the
Securities Act of 1933, as amended, each filing of the registrant&#146;s annual
report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act
of 1934, as amended, (and, where applicable, each filing of an employee benefit
plan&#146;s annual report pursuant to Section 15(d) of the Securities Exchange Act of
1934, as amended) that is incorporated by reference in the registration
statement shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.</P>
<P align=justify style="margin-left:5%;text-indent:5%;">(c) Insofar as indemnification for liabilities arising under
the Securities Act of 1933, as amended, may be permitted to directors, officers
and controlling persons of the registrant pursuant to the provisions described
in Item 15 above, or otherwise, the registrant has been advised that in the
opinion of the SEC such indemnification is against public policy as expressed in
the Securities Act of 1933 and is, therefore, unenforceable. In the event that a
claim for indemnification against such liabilities (other than the payment by
the registrant of expenses incurred or paid by a director, officer or
controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, that the registrant will,
unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the
Securities Act of 1933, as amended, and will be governed by the final
adjudication of such issue. </P>
<P align=center>II-3 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_24></A>
<P align=center><B>SIGNATURES </B></P>
<P align=justify style="text-indent:5%">Pursuant to the requirements of the Securities Act of 1933, the
registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this registration
statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the city of New York, state of New York, on October 23, 2015.</P>
<DIV align=right>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="50%" border=0>

  <TR vAlign=top>
    <TD align=left colSpan=2><B>ANAVEX LIFE SCIENCES CORP.</B> </TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="95%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left >By: </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="95%"><I>/s/
      Christopher Missling, PhD</I> </TD></TR>
  <TR vAlign=top>
    <TD align=left >Name: </TD>
    <TD align=left width="95%">Christopher Missling, PhD </TD></TR>
  <TR vAlign=top>
    <TD align=left >Title: </TD>
    <TD align=left width="95%">Chief Executive Officer, Principal </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="95%">Executive Officer and Chairman of </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="95%">the Board of Directors
</TD></TR></TABLE></DIV>
<P align=center><B>POWER OF ATTORNEY </B></P>
<P align=justify style="text-indent:5%">We, the undersigned officers and directors of Anavex Life
Sciences Corp., do hereby constitute and appoint Christopher Missling, PhD our
true and lawful attorney-in-fact and agent, with full power of substitution and
resubstitution, for him and in his name, place and stead, in any and all
capacities, to sign any and all amendments to this Registration Statement, and
to file the same, with exhibits thereto, and other documents in connection
therewith, with the SEC, granting unto said attorney-in-fact and agent, full
power and authority to do and perform each and every act and thing requisite are
necessary to be done in and about the premises, as fully to all intents and
purposes as he might or could do in person, hereby ratifying and confirming all
that said attorney-in-fact and agent, or his substitute or substitutes, may
lawfully do or cause to be done by virtue hereof. </P>
<P align=justify style="text-indent:5%">Pursuant to the requirements of the Securities Act of 1933,
this registration statement has been signed by the following persons in the
capacities and on the dates indicated below:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      ><B>Signatures</B> </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="53%"><B>Title(s)</B> </TD>
    <TD align=center width="2%"  >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="20%"
    ><B>Date</B> </TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="53%">&nbsp; </TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="20%" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      ><I>/s/ Christopher Missling, PhD</I> </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="53%">&nbsp; </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="20%" >October 23, 2015 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Christopher Missling, PhD </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="53%">Chief Executive Officer, Principal Executive
      Officer, </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="20%" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="53%">Director </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="20%" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      ><I>/s/ Sandra Boenisch</I> </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="53%">&nbsp; </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="20%" >October 23, 2015 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Sandra Boenisch </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="53%">Principal Financial Officer </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="20%" >&nbsp; </TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="53%">&nbsp; </TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="20%" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      ><I>/s/ Athanasios Skarpelos</I> </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="53%">&nbsp; </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="20%" >October 23, 2015 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Athanasios Skarpelos </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="53%">Director </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="20%" >&nbsp; </TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="53%">&nbsp; </TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="20%" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      ><I>/s/ Bernd Metzner, PhD</I> </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="53%">&nbsp; </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="20%" >October 23, 2015 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Bernd Metzner, PhD </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="53%">Director </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="20%" >&nbsp; </TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="53%">&nbsp; </TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="20%" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      ><I>/s/ Elliot Favus, MD</I> </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="53%">&nbsp; </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="20%" >October 23, 2015 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Elliot Favus, MD </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="53%">Director </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="20%" >&nbsp; </TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="53%">&nbsp; </TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="20%" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      ><I>/s/ Steffen Thomas, PhD</I> </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="53%">&nbsp; </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="20%" >October 23, 2015 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left >Steffen Thomas, PhD </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="53%">Director </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD align=left width="20%" >&nbsp; </TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_25></A>
<P align=center><B>EXHIBIT INDEX </B></P>
<P align=justify><B>ITEM 16. EXHIBITS</B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B>Exhibit</B> </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=left width="87%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center><B>No.</B> </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="87%"><B>Description of Exhibit</B> </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="87%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>4.1 </TD>
    <TD align=left width="2%" bgColor=#eeeeee>&nbsp;</TD>
    <TD align=left width="87%" bgColor=#eeeeee>Specimen Stock Certificate
      (incorporated by reference to an exhibit to our Registration Statement on
      Form SB-2 filed on January 13, 2005) </TD></TR>
  <TR vAlign=top>
    <TD align=left>4.2 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="87%">Form of Convertible Loan Agreement
      (incorporated by reference to an exhibit to our Form 8- K filed on April
      3, 2009) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee>4.3 </TD>
    <TD align=left width="2%" bgColor=#eeeeee>&nbsp;</TD>
    <TD align=left width="87%" bgColor=#eeeeee>8% Convertible Loan Agreement
      dated June 3, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </TD></TR>
  <TR vAlign=top>
    <TD align=left>4.4 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="87%">8% Convertible Loan Agreement dated June 19,
      2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on June 26, 2009) </TD></TR>
  <TR>
    <TD bgColor=#eeeeee>&nbsp; </TD>
    <TD width="2%" bgColor=#eeeeee>&nbsp;</TD>
    <TD width="87%" bgColor=#eeeeee>&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>5.1 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="87%">Opinion of Snell &amp; Wilmer, L.L.P.* </TD></TR>
  <TR>
    <TD bgColor=#eeeeee>&nbsp; </TD>
    <TD width="2%" bgColor=#eeeeee>&nbsp;</TD>
    <TD width="87%" bgColor=#eeeeee>&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>23.1 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="87%">Consent of BDO USA, LLP.* </TD>
  </TR>
  <TR>
    <TD bgColor=#eeeeee>&nbsp; </TD>
    <TD width="2%" bgColor=#eeeeee>&nbsp;</TD>
    <TD width="87%" bgColor=#eeeeee>&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>23.2 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="87%">Consent of Snell &amp; Wilmer, L.L.P.
      (incorporated from Exhibit 5.1) </TD></TR>
  <TR>
    <TD bgColor=#eeeeee>&nbsp; </TD>
    <TD width="2%" bgColor=#eeeeee>&nbsp;</TD>
    <TD width="87%" bgColor=#eeeeee>&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>24.1 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="87%">Power of Attorney </TD></TR></TABLE>
<P align=justify>* Filed herewith. </P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>s102056_exhibit5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Cop.: Exhibit 5.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_1></A>
<P align=justify><B>C. Thomas Burton, </B><B></B><B>Jr.</B> <BR><B>775.785.5433
<BR>tburton@swlaw.com </B></P>
<P align=center>October 23, 2015 </P>
<P align=justify>Anavex Life Sciences Corp. <BR>51 West 52<SUP>nd</SUP> Street,
7<SUP>th</SUP> Floor <BR>New York, New York 10019-6163 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="5%"  >&nbsp;</TD>
    <TD align=left >Re: </TD>
    <TD align=left width="90%">Registration Statement on Form S-3
  </TD></TR></TABLE>
<P align=justify>Ladies and Gentlemen: </P>
<P align=justify style="text-indent:5%">We have acted as your counsel in connection with the
registration statement on Form S-3 (together with all amendments to such
statement, the &#147;<U>Registration Statement</U>&#148;) relating to the registration of
(i) up to $100,000,000 of shares of Anavex Life Sciences Corp.&#146;s (the
&#147;<U>Company</U>&#148;) common stock, par value $0.001 per share to be offered by the
Company, (ii) up to $50,000,000 of shares of the Company&#146;s common stock, par
value $0.001 per share to be sold by the selling security holder described in
the Registration Statement, and (iii) up to 269,397 shares of the Company common
stock, par value $0.001 per share issued as a commitment fee to such selling
security holder (all collectively, the &#147;<U>Shares</U>&#148;). Capitalized terms used
in this letter which are not otherwise defined shall have the meanings given to
such terms in the Registration Statement </P>
<P align=justify style="text-indent:5%">You have requested our opinion as to the matters set forth
below in connection with the Registration Statement. For purposes of rendering
this opinion, we have examined the Registration Statement, the Company&#146;s
articles of incorporation, as amended, and bylaws, as amended, and the corporate
action of the Company that provides for the issuance of the Shares, and we have
made such other investigation as we have deemed appropriate. We have examined
and relied upon certificates of public officials and, as to certain matters of
fact that are material to our opinion, we have also relied on certificates made
by officers of the Company. In rendering our opinion, in addition to the
assumptions that are customary in opinion letters of this kind, we have assumed
the genuineness of signatures on the documents we have examined, the conformity
to authentic original documents of all documents submitted to us as copies, and
that the Company will have sufficient authorized and unissued shares of common
stock available with respect to any Shares issued after the date of this letter.
We have not verified any of these assumptions. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify>Anavex Life Sciences Corp. <BR>October 23, 2015 <BR>Page 2 </P>
<P align=justify style="text-indent:5%">This opinion is rendered as of the date of this letter and is
limited to matters of Nevada corporate law, including applicable provisions of
the Nevada Constitution and reported judicial decisions interpreting those laws.
We express no opinion as to the laws of any other state, the federal law of the
United States, or the effect of any applicable federal or state securities laws.
</P>
<P align=justify style="text-indent:5%">Based upon and subject to the foregoing, it is our opinion that
the Shares are duly authorized for issuance by the Company and, when issued and
paid for as described in the Registration Statement, will be validly issued,
fully paid, and nonassessable. </P>
<P align=justify style="text-indent:5%">We consent to the filing of this opinion as an exhibit to the
Registration Statement and to the reference to this firm in the related
Prospectus under the caption &#147;Legal Matters&#148;. In giving our consent we do not
admit that we are in the category of persons whose consent is required under
Section 7 of the Securities Act of 1933, as amended, or the rules and
regulations under such act. </P>
<P style="MARGIN-LEFT: 50%" align=justify>Very truly yours, </P>
<P style="MARGIN-LEFT: 50%" align=justify><i><u>/s/ Snell &amp; Wilmer L.L.P. </u></i></P>
<P style="MARGIN-LEFT: 50%" align=justify>  Snell &amp; Wilmer L.L.P. </P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>s102056_exhibit23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Cop.: Exhibit 23.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_1></A>
<P align=center><u>Consent of Independent Registered Public Accounting Firm</u></P>
<P align=justify>Anavex Life Sciences Corp. <br>
New York, New York </P>
<P align=justify>We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated December 29, 2014, relating to the consolidated financial statements of Anavex Life Sciences Corp. appearing in the Company&rsquo;s Annual Report on Form 10-K for the year ended September 30, 2014. </P>
<P align=justify>We also consent to the reference to us under the caption &ldquo;Experts&rdquo; in the Prospectus. </P>
<P align=justify>/s/ BDO USA, LLP</P>
<P align=justify>New York, New York <br>
October 23, 2015 </P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
